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SUMMARY 
 
The Mycobacterium tuberculosis Beijing strain family is a dominant strain family in most 
countries world wide, including South Africa. It has been suggested that this strain family has 
unique properties. These include the ability to evade the protective effect of Bacillus Calmette-
Guérin vaccination, spread more readily and the more frequent acquisition of drug resistance. 
These properties might be the reasons for the Beijing strain’s successful transmission. Comparative 
genomics have suggested that strains from the Beijing family can be broadly grouped into typical 
and atypical strains according to the presence or absence of an IS6110 insertion in the NTF region 
in the genome of Mycobacterium tuberculosis. Phylogenetic analysis showed that these two groups 
originated from a common progenitor. However, the atypical Beijing strain has only rarely been 
identified. The atypical Beijing strains are also not frequently associated with drug resistance, is 
attenuated and therefore do not spread readily. In contrast, by applying molecular epidemiological 
techniques, this study showed that an atypical Beijing strain acquired drug resistance and was 
spreading amongst tuberculosis re-treatment patients in the Eastern Cape province of South Africa. 
Further molecular analysis showed that this strain had a high fitness cost mutation in the rpoB 
gene, conferring rifampicin resistance. This correlates with in vitro generated rpoB mutants. The 
human immune deficiency virus/tuberculosis co-infection was found to be a significant co-factor, 
which allowed the atypical Beijing strain to be transmitted. Therefore, the attenuated atypical 
Beijing strain can overcome its fitness cost in high human immune deficiency virus burdened 
communities and may cause ongoing transmission. This raises concern for the spread of all drug-
resistant strains in vulnerable populations. 
 
By analysing a longitudinal reference database at the University of Stellenbosch, it has been 
observed that the strain dynamics within a strain family differs. There are large and small clusters 
in the Beijing strain family which is suggestive of more and less transmissible strains. Comparative 
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proteomic analysis by 2-D gel electrophoresis identified 64 protein spots which were different 
between a large and small cluster in the Beijing strain family. Similarly, 59 protein spots were 
found different between the attenuated atypical Beijing strain and the typical large Beijing cluster. 
By comparing the atypical Beijing strain to the small Beijing cluster it was found that 132 protein 
spots were different between the two strains. These results strongly suggest that differential 
expression of certain genes is associated with differential transmission of different Beijing sub-
lineages. The same may be true for other Mycobacterium tuberculosis strain families. It is likely 
that the bacterial genomic background play a more dominant role in the differential transmission of 
certain Mycobacterium tuberculosis strains, than host or programmatic related factors. A more 
comprehensive study, which involves the bacterium, host, and the tuberculosis control program, is 
needed to prove this assumption. 
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OPSOMMING 
 
Die Mycobacterium tuberculosis Beijing familie is ‘n prominent in meeste lande wêreld wyd, 
insluitende Suid-Afrika. Bevindings toon dat hierdie familie unieke eienskappe besit. Dit sluit in 
die vermoëe om die uitwerking van die Bacillus Calmette-Guérin vaksien te ontduik, maklik te 
versprei, en die vermoeë om meer gereeld middel weerstandigheid te verkry, en daarom so 
suksesvol is. Vergelykbare genomika het getoon dat stamme wat aan die Beijing familie behoort, 
in twee sub-groepe verdeel kan word naamlik, tipies en atipies as gevolg van die aanwesigheid of 
afwesigheid van ‘n spesifieke IS6110 invoeging in die NTF area van die Mycobacterium 
tuberculosis genoom. Filogenetiese analises het verder getoon dat die twee groepe ‘n 
gemeenskaplike oorsprong het maar die atipiese Beijing sub-groep is meer skaars en word nie 
dikwels met middel weerstandigheid geassosieer nie, en versprei daarom nie so maklik nie. In 
teenstelling, deur die toepassing van molekulere epidemiologiese tegnieke, het hierdie studie 
getoon dat daar ‘n atipiese Beijing stam in die Oos-Kaap provinsie van Suid-Afrika gevind is, wat 
wel middel weerstandig is en versprei het tussen tuberkulose pasiente wat weer op behandeling is. 
Verdere molekulere analises het getoon dat die atipiese Beijing stam ‘n hoë fiksheid verlies 
mutasie in die rpoB geen het wat rifampisien weerstandigheid veroorsaak. Hierdie bevinding 
korreleer met in vitro gegenereerde rpoB mutante. Die studie het gevind dat menslike 
immuniteitsgebrek-virus/tuberkulose ko-infeksie ‘n belangrike faktor was in die verspreiding van 
hierdie stam. Dus, die minder virulente atipiese Beijing stam kan fiksheid verlies oorkom in 
gemeenskappe wat belas is met menslike imuniteits virus, en kan dus voortdurende transmisie 
veroorsaak. Hierdie bevinding wek kommer oor die verspreiding van alle middel weerstandige 
Mycobacterium tuberculosis stamme in kwesbare gemeenskappe. Mycobacterium tuberculosis 
 
Die ontleding van ‘n aaneenlopende databasis van die Universiteit van Stellenbosch het getoon dat 
die dinamika van stamme binne ‘n stam familie verskil. Daar kom groot en klein groepe in die 
6 
 
Beijing stam familie voor wat bes moontlik op stamme wat met onderskeidelik ‘n hoe en lae 
oordraaglikheid dui. Vergelykende proteomiese analise deur middle van 2-D elektroforese het 64 
protein verskille opgelewer tussen ‘n groot en klein stam van die Beijing stam familie. Netso is 59 
protein verskille gevind toe die groot tipiese Beijing stam en die geattenueerde atipiese Beijing 
stam vergelyk word. “n Vergelyking  tussen  die klein tipiese Beijing stam en die atipiese Beijing 
stam het 132 protein verskille getoon. Hierdie resultate laat ‘n sterk vermoede dat differensiele 
uitdrukking van sekere gene geassosieer kan word met differensiele oordraag van verskillende 
Beijing stamme. Dieselfde mag ook geld vir ander Mycobacterium tuberculosis stam families. Dit 
is moontlik dat die genomiese agtergrond van die bakterium ‘n meer dominante rol by die 
differensiele oordraag van sekere Mycobacterium tuberculosis stamme het as ander faktore 
rakende die draer van die tuberkulose infeksie, of die tuberkulose-beheerprogram. Om hierdie 
aanname te staaf sal ‘n meer omvattende studie wat die Mycobacterium tuberculosis bakterium, 
die draer, en die Mycobacterium tuberculosis tuberkulose beheerprogram betrek, nodig wees. 
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LIST OF ABBREVIATIONS 
 
°C   :  degree Celsius 
µl   :  microlitres 
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g   :  grams 
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LJ   :  Loewenstein Jensen 
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M. tuberculosis :  Mycobacterium tuberculosis 
MgCl2   :  Magnesium chloride 
min.   :  Minute 
MIRU   :  Mycobacterial interspersed repetitive units 
ml   :  millilitres 
mM   :  millimoles 
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Na2S2O3  :  Sodium thiosulfate  
((NH4)2SO4)  :  Ammonium sulfate 
ng   :  nanograms 
OD   :  optical density 
PMSF   :  phenylmethylsulfonyl fluoride 
PBS   :  Phosphate buffer saline 
PCR   :  Polymerase chain reaction 
PE   :  Port Elizabeth 
KH2PO4  :  Potassium dihydrogen phosphate 
pM   :  picomoles 
RFLP   :  Restriction Fragment Length Polymorphism 
RIF   :  rifampicin 
rpm   :  Revolutions per minute 
RRDR   :  rifampicin resistance determining region 
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SA   :  South Africa 
SDS   :  Sodium dodecyle sulphate 
SDS-PAGE  :  Sodium dodecyle sulphate polyacrylamide gel 
                                                      electrophoresis 
Spoligo  :  spacer oligo 
SNP   :  Single nucleotide polymorphism 
TB   :  tuberculosis 
TBE   :  Tris/Borate/EDTA 
TE   :  Tris/EDTA 
Tm   :  melting temperature 
TRIS   :  Trishydroxymethylaminomethane 
U   :  Units 
VNTR   :  Variable numbers of tandem repeats 
WC   :  Western Cape 
WCL   :  Whole cell lysate 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 BACKGROUND 
 
Mycobacterium tuberculosis (M. tuberculosis) is one of the most successful human pathogens. It is 
responsible for tuberculosis (TB) in one third of the world’s population and cause many mortalities 
each year (30). For many years this pathogen has been studied to determine why it so successful. A 
great amount of knowledge has been obtained about M. tuberculosis, the host, and environment 
through different studies, but still not enough is known to stop the disease from causing epidemics 
and deaths. The good news is that TB is treatable with anti-TB drugs. However the bacterium has 
many protecting mechanisms, of which one is developing spontaneous mutations in chromosomal 
genes that are specific targets of the anti-TB drugs, causing the bacterium to become resistant to the 
drugs (2,7). These chromosomal mutations can also be selected for as a result of inadequate 
treatment or failure by the patient to comply with adequate treatment (29). 
 
TB drug resistance is a major problem worldwide. Treatment of patients infected with drug-resistant 
M. tuberculosis strains, has to be prolonged and less effective second-line drugs that are more toxic 
and more expensive, have to be used (5). M. tuberculosis strains become multi-drug resistant 
(MDR) when they develop resistance to at least two of the most effective first-line anti-TB drugs, 
isoniazid (INH) and rifampicin (RIF) (14) but in addition may also be resistant to any other anti-TB 
drugs. Recently, the TB drug resistance problem has been amplified greatly by the discovery of 
extensively drug-resistant (XDR) TB strains. These are M. tuberculosis strains that have developed 
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MDR as well as resistance to any fluoroquinolone and also one of the three injectable second-line 
drugs (capreomycin, kanamycin and amikacin) (5).  
 
There are many factors that contribute to the spread of drug-resistant strains which include, non-
compliance of the patients to their anti-TB treatment therapy (29); the quality of TB control 
programs (3); the relative fitness of drug-resistant M. tuberculosis strains ; as well as their genetic 
backgrounds (9). Fitness, virulence, pathogenicity, and transmission are tightly linked as 
demonstrated diagrammatically in Figure1. The more fit the bacterium, the more virulent it is and 
the more it can be transmitted. The fitness of the bacterium can therefore be defined as a combined 
measure of the bacterium’s ability to survive, reproduce, and to be transmitted to other individuals 
under certain environmental conditions which then cause disease or pathogenesis in the newly 
infected individual (6,15). In other words the bacterium’s ability to infect, persist, and proliferate, 
causing disease and then transmitting to a secondary host. Environmental factors such as poverty, 
malnutrition, stress, overcrowding, and exposure to environmental mycobacteria, might also play a 
role (8,11,12,17). In addition, poor TB control programs may lack the ability to contain the spread 
of certain fit M. tuberculosis strains.  
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Figure1. The diagram illustrates the relationship between the fitness, virulence, pathogenecity, and 
transmission of M. tuberculosis and as well as environmental factors. 
 
Drug-resistant M. tuberculosis strains are often associated with a reduced competitive ability when 
compared to drug-sensitive M. tuberculosis strains (6,9,15). Certain studies showed that the fitness 
of a drug-resistant bacterium is reduced compared to that of a drug-sensitive bacterium; it was 
therefore concluded that there is a cost to being drug-resistant (1,9). This fitness cost depends on 
specific drug resistance conferring mutations. The degree to which the mutations affect the fitness 
of the bacterium varies with the specific drug resistance conferring mutation, the environment, and 
the genetic background of the strain (9). Several studies have found that some bacteria obtained 
secondary mutations which seemed to reduce the fitness cost of the first mutations (2,6,9,15,19). 
Therefore the bacterium can adapt to this fitness cost by gaining secondary mutations that can 
compensate for the cost of drug resistance. 
 
Environment 
Fitness 
Pathogenecity Transmission 
Virulence 
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RIF is one of the most important first-line anti-TB drugs and is a very good marker for the detection 
of MDR-TB (4). This drug interacts with the β-subunit of the RNA polymerase encoded by the 
rpoB gene in M. tuberculosis, causing inhibition of the early steps of transcription (13,16). In 
addition to the early bactericidal effect on metabolically active bacteria, RIF also exhibits late 
sterilizing action on semi-dormant bacteria undergoing short bursts of metabolic activity (22). 
Among clinical isolates RIF-resistance is almost exclusively due to mutations in an 81 base pair 
region called the RIF resistance-determining region (RRDR) in the rpoB gene (15,18,24). The 
fitness cost of drug resistance has been clearly demonstrated during the evolution of RIF-resistance 
in clinical isolates and in vitro experiments, where it has been shown that different mutations 
conferring RIF-resistance occur at different rates (2,9,13,16) and the frequency at which mutations 
are observed correlates directly with their fitness cost. It has been shown in vitro and in clinical 
isolates that mutations at codon 531 of rpoB exhibited the lowest or nearly no fitness cost, which 
explains why this specific mutation is so frequently observed in in vitro generated rpoB mutants as 
well as clinical isolates (2,6,9,15). In contrast, mutations at codons 511, 516, 519 and 529 of rpoB, 
are examples of high fitness cost mutations, conferring RIF-resistance (21). Accordingly, the 
molecular epidemiology of drug-resistant strains of M. tuberculosis should correspond to fitness 
cost and overall strain fitness.  
 
Scientists in the Division of Molecular and Cellular Biology, Stellenbosch University, SA, have 
studied TB for the last decade and all the data gathered from those studies were deposited into a 
longitudinal reference database. The database contains phenotypic and genotypic data of different 
M. tuberculosis strains, as well as clinical and demographic information from the patients infected 
with these strains, from different regions in SA as well as from a few other countries in Africa. 
Upon analysing the database we made a number of interesting findings related to this study. We 
have observed that the TB epidemic in SA is driven predominantly by transmission of drug 
susceptible- as well as drug-resistant M. tuberculosis strains (10,20,23,25-28). Large drug-resistant 
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LARGE 
 
Small cluster 
Unique strain 
strain families (defined as strains with closely related DNA fingerprints) have been observed (28) 
but what we have noticed is that within these large strain families are certain clusters that are more 
dominant than others (Figure 1.2) implying that they are transmitted more and are therefore more 
fit. These dominant clusters will be referred to in this thesis as large clusters (defined by more than 
10 isolates with identical or closely related DNA fingerprints and genotypic characteristics). There 
are also clusters within these large strain families that consist of only a few isolates (2-5 isolates 
with identical or closely related DNA fingerprints), implying that they are less transmitted and 
therefore less fit. They will be referred to as small clusters. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.2. A representation of a large M. tuberculosis strain family consisting of large and small clusters, as 
well as strains with unique DNA fingerprints.  
 
Some of the questions that we will attempt to answer in this study are, why some strains within the 
same strain family are more transmitted than others? Are they more fit and what makes them more 
fit? By using different molecular methods, we attempted to answer these questions. 
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1.2 PROBLEM STATEMENT 
Drug resistance in M. tuberculosis is a major problem worldwide as well as in SA. This form of the 
bacterium is able to overcome the host defences, TB control programme efforts, as well as possible 
evolutionary costs. The study was designed to try and understand on genomic and proteomic level 
mechanisms that might give certain M. tuberculosis strains an advantage over others, in their ability 
to cause ongoing drug-resistant TB. 
 
1.3 HYPOTHESIS 
Transmission of drug resistant strains is due to a combination of (1) strain fitness, (2) drug tolerance 
and (3) short comings in the TB control program, which include the social anthropology of patients.  
 
The main focus of this study is on strain FITNESS. 
 
1.4 AIMS 
(1) To test the hypothesis that high fitness cost mutations would not be found in the Beijing strain 
family and that the attenuated form of Beijing strains would not actively spread. 
(2) To discover the proteins that make large clusters of drug-resistant Beijing isolates more fit than 
small clusters of drug-resistant Beijing isolates. 
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1.5 EXPERIMENTAL APPROACH  
The experimental approach of this study was to make use of existing data on drug-resistant M. 
tuberculosis strains from different settings in SA, and to use different molecular methods to get a 
better understanding of the drug-resistant TB epidemic in SA. Genomic methods such as DNA 
sequencing were used to characterise M. tuberculosis isolates. Proteomic methods such as 2-
Dimentional Gel Electrophoresis were used to identify new proteins that might play an important 
role in the virulence/fitness of drug-resistant M. tuberculosis strains.  
 
 
 
 
 
 
This thesis was structured according to the instructions of the Journal of Clinical Microbiology. 
References, figures and tables relevant to each chapter will be given in each chapter.  
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2.1 Background 
 
The tuberculosis (TB) disease burden has reach frightening proportions in certain countries and is 
cause for much concern worldwide (94). Mycobacterium tuberculosis (M. tuberculosis), the 
causative organism of TB, is responsible for 2-3 million deaths annually and one-third of the world’s 
population is infected with this bacterium (94). Only a small proportion (5%) of those infected 
develop primary TB (94). TB is a disease that is treatable with chemotherapy using anti-TB drugs 
but the emergence of drug-resistant M. tuberculosis strains, which include multi drug-resistant 
(MDR) strains (strains that are resistant to at least two of the most effective front-line anti-TB drugs, 
isoniazid (INH) and rifampicin (RIF)) (45) as well as extreme drug-resistant (XDR) strains (strains 
that are resistant to most of the anti-TB drugs available) (49,96) has made it very difficult to treat 
and cure TB patients leading to the high mortality rates seen today.  
 
For any bacteria to cause disease there must be an interaction between the bacterium and the host. 
Some bacteria are more aggressive in their ability to cause disease and those bacteria are usually 
referred to as being more virulent. Many bacteria produce “virulence factors” such as spores or 
toxins to assist them in causing disease, but for M. tuberculosis, no clear virulence factor could be 
identified yet. Defining virulence in tuberculosis (TB) is complicated and ill defined. M. tuberculosis 
virulence can be divided into four different components that include infection, pathogenicity, 
transmission, and active disease. Infection, pathogenicity and transmission are tightly linked in 
causing active disease and the different components are experimentally difficult to study. As a result 
there are quite a number of definitions for virulence in TB. The most common definitions used 
include mortality, which is defined as the percentage of infected host that die (72), it has also been 
defined as the time that it took the host to die after being infected (72). Other definitions include, the 
capacity to produce disease, and disease severity (55); and the ability to cause progressive pathology 
in the lungs (22,60). 
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Transmission is considered a key component of virulence in M. tuberculosis. Results from 
molecular epidemiological studies suggest that some M. tuberculosis strains are more dominant in 
certain regions because of their ability to transmit (32,40,88,90,92), and it is suggested that these 
strains are more virulent, which can be seen as a reflection of the fitness of the strain . The 
transmissibility or fitness of a bacterium is determined by the bacterium’s ability to infect a 
susceptible host, to persist and proliferate in that host and than causing disease in such a manner so 
that it can be transmitted to a secondary host (18). 
 
Humans cannot be used as a model to study M. tuberculosis pathogenesis. Therefore, alternative, 
but appropriate in vivo and in vitro experimental models that mimic the specific environments of 
the natural host are required to identify the determinants of M. tuberculosis virulence in humans. It 
is necessary to have good models for studying the mechanisms and determinants of virulence in M. 
tuberculosis since this will help to understand this extremely successful pathogen.  
 
This review describes some of the major methodologies and models that are currently used to 
study virulence in M. tuberculosis. These models are used to study the molecular and physiological 
mechanisms of pathogenesis, pathology, and immunology of the disease, thus helping us to gain 
insight into the pathogen–host interaction in an attempt to understand how the bacterium evade and 
survive host defences and cause disease. The first part of the review will focus on the major 
models that are used and the second part on the molecular methodologies that are used to study 
virulence in conjunction with the experimental models. 
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2.2 TISSUE CULTURE MODELS 
 
TB infection begins when M. tuberculosis reach the pulmonary alveoli where they invade and 
replicate within alveolar macrophages (53). The bacteria are then picked up by dendritic cells, 
which can transport the bacilli to local lymph nodes (10). From there the bacteria get into the 
bloodstream and are transported further to other tissues and organs. Progression from TB infection 
to TB disease occurs when the TB bacilli overcome the immune system defences and begin to 
multiply. 
 
Although some animals acquire disease in appropriate tissues and organs when infected with 
human pathogens, the immune and other physiological responses encountered in an animal model 
may be different from those that the bacteria would engage during human disease (65). In those 
instances model systems containing human cells may be more appropriate (7). These tissue culture 
models may be mono-layered or multiple-layered (7). They are much easier to work with than 
animal models and results are obtained much faster. Tissue culture models may include 
macrophages (53), dendritic cells (DCs) (10), or pneumocytes (53).  
 
2.2.1 Macrophage models 
Macrophage models are very useful for studying virulence of M. tuberculosis since these are the 
cells that are primarily infected by M. tuberculosis (20). Human- or mice macrophages can be 
used, but human macrophages are difficult to obtain (72). Macrophages can be obtained as primary 
cultures or immobilised cell lines, and although primary human macrophages are the models of 
choice since they are more representative of the actual in vivo situation, they are not so readily 
obtainable than mice macrophages and are also more variable (72).  
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2.2.2 Dendritic cells 
Dendritic cells (DCs) produce numerous amounts of cytokines involved in host defence 
mechanism and therefore play a critical role in innate immunity as well as in the initiation of an 
adaptive immune response (10,39,54). These cells are considered to be better antigen processors 
and presenters than macrophages. They can also capture antigens against which immunity is 
normally avoided. They are also migratory and therefore may play an important role the 
dissemination of M. tuberculosis. They can be derived from human peripheral blood or mouse 
bone marrow, and are considered to be the most potent antigen presenting cells (10).  
 
2.2.3 Pneumocyte models 
Several in vitro studies have shown that M. tuberculosis enter and replicate in pneumocytes, but 
the interaction is short lived because the cells proceed rapidly to death releasing a cascade of 
inflammatory chemokines and cytokines (70). Other studies, where they made use of transcytosis 
assays conducted with pneumocyte monolayers, indicated that pneumocytes internalized the 
bacteria, but with low efficiency, the bacteria is then exocytosed at the basolateral surface of the 
cell (70). It was therefore concluded that the pneumocytes might play a role in the rapid 
dissemination of the bacteria to other tissues and organs (70). 
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2.3 ANIMAL MODELS 
 
The major animal models used to study M. tuberculosis virulence include mice, guinea pigs, 
rabbits (72), and to a much lesser extend the non-human primates (15,46,51). A number of aerosol 
delivery systems have been developed for the infection of animal models (17). In some of the 
experiments, the animals are exposed to aerosols of M. tuberculosis that are deposited directly into 
the alveolar spaces of the lungs. This is done using aerosol exposure chambers (Figure 1.1) that 
have been designed so as to produce uniform clouds of droplet nuclei, which result in pulmonary 
infection of the animals simultaneously. The animals mentioned above, develop disease that 
exhibits many of the important features of human TB (52). These include the development of 
granulomas in the lung and other tissues, the onset of a strong immune response mediated by CD4 
and CD8 T cells, temporary control of the accumulation of bacilli in the lungs and other organs, 
and depending on the animal species, persistent infection that remains under control for many 
months, as well as the eventual (continuing bacterial proliferation leading to disease progression 
and death) increase and uncontrollable infection followed by death. In addition, these models are 
appropriate and very useful for the screening of new anti-TB drugs and vaccines since it was found 
that oral therapy with first-line anti-TB drugs as well as vaccination with BCG results in 
significant protection in all of the models (52).  
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Figure1.1. Custom-made aerosol exposure chamber, in which small experimental animals can be infected by the  
reproducible deposition of very small numbers of virulent Mycobacterium tuberculosis directly into the  
alveolar spaces of the lung (52). 
 
2.3.1 Mouse model 
There are many reasons why this model is the most used to study TB. The mouse model has very 
well studied genetics (31,52,62). The mouse immune system is very well characterised and many 
immunological reagents for the mouse model are commercially available. The cost of purchasing 
and maintaining mice is low, and this animal can easily be housed under BSL3 conditions. The 
genetic manipulation of the mouse is also highly advanced. However, there are certain limitations 
that this model cannot overcome. The disease process is significantly different than that of humans 
(24,52). The granulomas do not progress to necrosis, caseation and liquefaction (24). The mouse can 
sustain very high levels of M. tuberculosis without progressing to disease for months and it has 
increased pathology due to high bacterial numbers (52). 
 
Over the years quite a number of mouse models have been developed which include 
immunodeficient mouse models, gene-disrupted and transgenic mouse models, as well as 
immunosenescent mouse models (31). These models were very helpful to define the pattern of TB 
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disease (31), to investigate the strong immune response to TB that mice show, as a cost effective 
model for the evaluation of drugs, and to study virulence of M. tuberculosis (31). Some of the inbred 
mouse strains used are grouped as highly susceptible models (CBA, DBA/2, C3H, and 129/SvJ) and 
highly resistant models (e.g. BALB/c and C57BL/6) (16). 
 
The mouse model was very important in certain virulence studies, where M. tuberculosis strains 
that were found to be more virulent than others, in humans, were also more virulent in mice. In 
contrast, other studies showed that strains that were found more virulent in humans were not 
necessarily more virulent in mice (67). In another study, it was found that a strain of M. 
tuberculosis that was believed to be virulent, only have the ability to induced a stronger immune 
response, therefore caused more tuberculin skin test conversions than other strains, but was 
actually less virulent (60).  
2.3.2 Guinea pig model 
The guinea pig model is considered the most susceptible animal model of TB. Impressive caseous 
necrosis, very similar to that in humans, develops in the lungs. Chronic progressive disease develops 
after very low-dose infection. This model has many significant similarities to humans. They are 
immunologically and hormonally closer to humans then mice. There are significant similarities in 
the physiology of the pulmonary tract, especially the response lung to inflammatory stimuli. They 
respond well to anti-TB drugs and can be successfully protected by BCG and some experimental 
vaccines. Several cytokine and chemokine genes of the guinea pig have also been cloned. This 
model is relatively inexpensive and easy to house under BSL3 conditions compared to larger animal 
models. 
 
To study virulence of M. tuberculosis, this model has been used to compare different M. 
tuberculosis strains (grown under different conditions) to determine whether there is a difference 
in the ability to cause infection in the lung, and in the dissemination of the bacterium to other 
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organs. In a study done by Williams et al. (95), female Dunkin-Hartley guinea pigs were used and 
they made use of a 3-jet Collison nebulizer together with a Henderson apparatus (this apparatus 
allows the delivery of aerosols directly to the snout of the animal without contamination of the fur 
or eyes) to infect the animals with M. tuberculosis (17). The growth conditions used for these 
experiments must be relevant to the host environment. Two M. tuberculosis strains were compared 
under stress conditions and they found that infectivity as well as dissemination increased under 
these conditions (17). In another study done by Russell K. Karls et al. (42), guinea pigs were used 
to identify sigma factors that may be important regulators of virulence . Secondary sigma factors 
sense specific stress signals and coordinate expression of genes encoding functions that facilitate 
bacterial adaptation to those particular stresses. In this study, a Madison aerosol chamber was used 
to deliver M. tuberculosis into the lungs of the guinea pigs (42). Again, female Dunkin-Hartley 
guinea pigs were used. They found that sigma factor C (sigC) is an important regulator of 
virulence, because sigC deficient M. tuberculosis resulted in fewer and smaller lung and spleen 
granulomas (42) SigC is responsible for mediating adaptive survival of M. tuberculosis upon 
entering the host environment (42). 
 
Recently, the guinea pig model has been advanced with the establishment of an airborne infection 
research (AIR) facility in South Africa in partnership between the South African Medical Research 
Council, CDC and USA Harvard School of public health (73). The facility includes a wing of an 
MDR-TB referral hospital converted into an experimental facility consisting of a) a clinical unit, 
providing human-source infectious MDR-TB aerosols or aerosol of bacteria through a nebulyzer, 
b) separate guinea pig rooms coupled to each of the clinical units, and c) a dedicated specialist TB 
laboratory. Air from the clinical unit is conveyed to the animal exposure chamber under controlled 
conditions. Guinea pigs are tested regularly for infection and sacrificed at predetermined times for 
additional experiments. This facility currently does not measure animal-to-animal transmission but 
can measure infection and pathogenicity after aerosolizing bacteria in the clinical room. There are 
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no published results on the experimental validation of the facility to measure transmission of 
bacteria through aerosolization and the facility is extremely expensive to use. 
 
2.3.3 Rabbit model 
The rabbit model is useful for comparison studies between virulent M. tuberculosis isolates 
(47,83), as well as modelling tuberculous meningitis (84). Rabbits can be infected by aerosol by 
using a nose-only system. The aerosols are generated in a class 3-biosafety glove box cabinet 
under negative pressure or in a completely contained biosafety level 4 air-locked area. The 
biosafety level 3-exposure chamber is a 16-liter Plexiglas box with one side containing a circular 
latex dam with a cut-out into which the snout (nose and mouth) of the rabbit is inserted (8,47). 
 
A spectrum of disease that represents many of the specific stages of human disease develops in these 
models, which is an advantage over both mouse and guinea pig models (47). They are relatively 
resistant to M. tuberculosis because they are able to contain disease caused by virulent M. 
tuberculosis isolates. Lung granulomas closely resemble the human granuloma, with caseous 
necrosis as well as cavity formation (47). However, these animals are difficult to house under BSL3 
conditions, therefore increasing the cost of this model (24). 
 
In 1999, Bishai et al. (8) made use of Lurie’s tubercle count method to investigate the virulence of 
H37Rv compared to that of CDC1551. This method is based on the hypothesis that the more 
virulent the bacterium, the greater its resistance to destruction by both alveolar macrophages and 
the host immune response (8). The bacterium that is more virulent will therefore produce more 
grossly visible tubercles. Apart from the number of visible tubercles in the lung, the size of the 
tubercle as well as the number of bacilli culturable from the tubercles is important when 
determining virulence (8). For the experiment, Bishai et al. used 12 rabbits, 6 were infected with 
H37Rv and the other 6 were infected with strain CDC1551 by using an aerosol exposure chamber. 
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They found that the rabbits infected with the different strains produced equal numbers of grossly 
visible tubercles, but the tubercles produced by CDC1551 were smaller and contained fewer 
bacilli. They therefore concluded that CDC1551 was less virulent in rabbits than H37Rv (8). 
Another study done Manabe et al. (47) investigated tuberculosis infection in rabbits with 3 
different strain which include M. tuberculosis, CDC1551 and Erdman. The rabbits were also 
exposed to the bacteria via an aerosol exposure chamber. They found that fewer inhaled bacilli of 
the Erdman strain than that of H37Rv were required to produce a visible tubercle/lesion in the 
rabbits at 5 weeks post infection (47). The rabbits infected with H37Rv had lesions that healed in 4 
to 6 months whereas lesions in half of the rabbits infected with the Erdman strain had healed at 
that time. In this study the concluded that the Erdman strain is more virulent than H37Rv (47). 
They decided to do a H37Rv-based microarray to investigate this further and found that a gene 
called Rv3428c in RD6 was absent in Erdman (47). RD6 is also known to be deleted in 
CDC1551as well as in many strains of M. bovis (12). They concluded that the deletion of gene 
Rv3428c might in part be the reason for the different patterns of disease produced by the strains in 
the rabbit. 
 
2.3.4 Non-human primate model 
Several species of monkeys are susceptible to infection with M. tuberculosis, but the two species 
most used in studies, is the Cynomolgus monkey, Macaca fascicularis (15,26,46) and the Rhesus 
monkey, Macaca mulatta (51), which are referred to as Old World monkeys. These animals are 
closely related to humans and are quite susceptible to infection with M. tuberculosis (51). They can 
also be infected with very low doses of virulent M. tuberculosis via the respiratory route resulting in 
disease, which closely resembles the human disease (25). They exhibit antigen-induced T-
lymphocyte activity and can be successfully protected by BCG. They represent by far the most 
closely related conditions found in humans than any of the other animal models (46). However, 
monkeys are very expensive to maintain, and are difficult to handle and house under BSL3 
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conditions (25). Much less research has been done on this model; therefore literature available on 
this model is very limited.  
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2.4 MOLECULAR METHODOLOGIES THAT CAN BE USED TO STUDY VIRULENCE 
OF M. TUBERCULOSIS. 
 
Transmission is considered a key component of virulence in M. tuberculosis. The transmissibility 
of a bacterium is determined by the bacterium’s ability to infect a susceptible host, to persist and 
proliferate in that host and than causing disease in such a manner so that it can be transmitted to a 
secondary host (18). Transmission events of M. tuberculosis to new hosts are difficult to study in 
any animal model other than humans. Studying transmissible clinical isolates, as measured by 
molecular epidemiological studies, has been the approach to this problem. Several studies using 
molecular epidemiological methods, that document transmission of drug susceptible and drug 
resistant M. tuberculosis strains in specific settings/populations, have been documented 
(11,14,28,48,71,81,89,90). Results from these studies suggest that some M. tuberculosis strains are 
more dominant in certain regions because of their ability to transmit, and it is suggested that these 
strains are more virulent which is then a reflection of the fitness of the strains (29).  
 
Some of the molecular epidemiological methods currently used include IS6110 restriction 
fragment length polymorphism (RFLP) analysis (87), spoligotyping (41), MIRU-VNTR (58), SNP 
analysis (66), and genomic deletion analysis (36,43,57,85,86). The advantages and disadvantages 
of these methods are summarised in Table 2.1.  
 
IS6110 RFLP analysis 
IS6110 RFLP is based on the detection of the insertion sequence IS6110 which is present in different 
copy numbers (between 0 and 25 copies) in the M. tuberculosis complex and is integrated at various 
chromosomal sites. A pattern can be generated according to the IS6110 insertion sequences present 
in a particular M. tuberculosis strain. DNA is extracted, purified and digested with the restriction 
enzyme PvuП which cleaves the IS6110 insertion sequence at a single site. The digested DNA 
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fragments are separated overnight on an agarose gel after which it is transferred to a DNA 
membrane. The hybridizing digested fragments are detected by a chemilluminescence reaction that 
is initiated by two substrates. The RFLP patterns can be detected on a light-sensitive film (50,87).  
 
Spoligotyping 
Spoligotyping is a technique that is based on the detection of DNA polymorphisms in the direct 
repeat (DR) region in the M. tuberculosis genome. The DR region contains a variable number of 
short direct repeats interspersed with non-repetitive spacer sequences (34). M. tuberculosis strains 
vary in the number of DRs and in the presence or absence of particular spacer sequences (30). DRs 
are very well conserved among M. tuberculosis strains and are used as targets for in vitro DNA 
amplification in which the variation in the spacers is used to obtain different hybridization patterns 
of the amplified DNA with multiple synthetic spacer oligonucleotides, which are covalently bound 
to a membrane. The spacer sequences are first amplified by PCR and then hybridized to a 
membrane containing the synthetic spacer oligonucleotides. Hybridisation is detected by 
streptavidine-peroxidase conjugate and a substrate which results in a chemilluminescence reaction 
that can be detected on film (41). 
 
MIRU-VNTR typing 
MIRU-VNTR typing is high-throughput PCR analysis of M. tuberculosis genomic loci that contain 
variable-number tandem repeat (VNTR) sequences. M. tuberculosis strains can be typed by a 
numerical code corresponding to the numbers of VNTRs in 12 different loci that contain novel 
genetic elements named mycobacterial interspersed repetitive units (MIRUs) (78,79). These loci 
have formed the basis of a PCR-based typing method that has discrimination similar to that of high 
IS6110 copy number strains and better for low copy number strains (77). 
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SNP analysis 
A SNP (single nucleotide polymorphism) is a variation occurring when a single nucleotide (or other 
shared sequence) differs between members of a species (or between paired chromosomes in an 
individual). Almost all common SNPs have only two alleles. SNPs may fall within coding 
sequences of genes, non-coding regions of genes, or in the intergenic regions between genes. SNPs 
within a coding sequence will not necessarily change the amino acid sequence of the protein that is 
produced, due to degeneracy of the genetic code. A SNP in which both forms lead to the same 
polypeptide sequence is termed synonymous (sometimes called a silent mutation) (sSNP) - if a 
different polypeptide sequence is produced they are non-synonymous (nsSNP) (50). SNPs that are 
not in protein-coding regions may still have consequences for gene splicing, transcription factor 
binding, or the sequence of non-coding RNA. SNPs can be detected by DNA sequencing. 
 
Genomic deletion analysis 
This method is based on large-sequence polymorphisms (LSP) which have been identified by 
comparative genomic analysis of H37Rv and CDC1551 (23). LSPs mainly occur as a result of 
genomic deletions (13). Analysis can be performed by a PCR-based method or by automated 
GeneChip techniques, using deleted fragments (86).  
 
These techniques have detected genotypic variations among M. tuberculosis strains and can be 
used to obtain fingerprints for different isolates of M. tuberculosis (41,56). RFLP studies are used 
to discriminate between individuals by highlighting minor chromosomal differences/changes that 
are not always related to a variation in phenotype (63). 
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Mouse models have indicated that there is a difference in pathogenicity in different clinical M. 
tuberculosis strains, but the mouse or any other animal model is unable to measure transmission 
(4,61). In the absence of a mouse model to directly measure transmission, investigators have used 
competition assays on culture medium and cell lines to measure virulence and strain fitness (48). 
Some of the reports indicate that drug resistant strains of M. tuberculosis spread less readily than 
drug-susceptible strains (27), others show no difference in disease transmission (80), and we have 
shown larger drug resistant clusters than susceptible clusters within the same strain family (75).  
 
2.5 DOWNSTREAM METHODOLOGIES TO FURTHER STUDY VIRULENCE. 
The molecular/downstream methods that can be used to further investigate virulence factors that 
might have been identified, during for example animal studies, are discussed below. 
 
2.5.1 Whole genome sequencing 
Whole genome sequencing is one of the most advanced technologies today, and can be used to get a 
much better understanding of M. tuberculosis virulence (19). Comparative genomic analysis can be 
used to get insight into differential transmission events of M. tuberculosis and genetic loci that might 
be involved. A small number of genomes have been fully sequenced yet. These include the 
laboratory strain H37Rv (19), the clinical strain CDC1551 (23), M. tuberculosis strain C, and 
Haarlem (1). The first whole genome sequence of an MDR strain originates from our strain 
collection and the sequence was released recently by SAMJ (91). With Whole genome sequencing, it 
is now possible to compare the genomes of more or less fit M. tuberculosis strains, as defined by 
molecular epidemiological methods (2,5,19,21).  
 
2.5.2 Microarray analysis 
Microarray analysis is a high throughput technique that can be used to analyse every gene in the 
genome simultaneously (97). Microarrays are made up of DNA sequences (genomic DNA – coding, 
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intergenic, or non-coding regions; complementary DNA; and oligonucleotides that cover all of the 
open reading frames in the genome or only specific ones from specific genes of interest) that serve 
as probes that attached to a solid surface such as glass slides, membranes, or silicon chips (69). The 
sample of interest is fluorescently labelled and hybridized to the array. A confocal microarray 
scanner such as Affymetrix 428 duel-laser will detect the fluorescence signal and will generate a 
gene expression profile (35). The data obtained from the array can then be linked to a gene identity 
grid which specifies which genes were immobilised on the microarray spots. The data are further 
analysed using Genespring software which will reveal the identity of the genes, the location of the 
genes, and whether they are up or down regulated, etc. (93). A list of candidate genes can be 
compiled which can be used in gene manipulation (knock out) studies to identify the molecular 
mechanisms associated with a specific phenotype. For example, microarray analysis can be done on 
two strains, one considered more virulent than the other. From the results of the analysis, a list of 
candidate genes that differ between the two strains and that might play a role in 
virulence/transmission can be compiled and used for further investigations (44).  
 
2.5.3 Proteomics 
 
Proteomics is the large-scale study of proteins, particularly their functions and structres (3,9). 
Proteins are important parts of living organisms, as they are the main components of the 
physiological metabolic pathways of cells. Proteomics is often considered the next step in the study 
of biological systems, after genomics. It is much more complicated than genomics, mostly because 
while an organism's genome is rather constant, a proteome differs from cell to cell and constantly 
changes through its biochemical interactions with the genome and the environment. One organism 
has very different protein expression in different parts of its body, different stages of its life cycle 
and different environmental conditions. Proteins are also very complex relative to nucleic acids. 
E.g., in a human there are about 25 000 identified genes but an estimated >500 000 proteins that are 
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derived from these genes. This increased complexity derives from mechanisms such as alternative 
splicing, protein modification (glycosylation, phosphorylation) and protein degradation which lead 
to transcripts giving rise to more than one protein. Many proteins also form complexes with other 
proteins or RNA molecules, and only function in the presence of these other molecules (59).  
 
Proteomics have played an important role in the discovery of biomarkers, such as markers that 
indicate a particular disease (68). Specific protein biomarkers identified by proteomics, can be used 
to diagnose disease. It is also very useful for characterising cells and tissues; because there are so 
much more proteins in the proteome than protein-coding genes, protein diversity cannot be fully 
characterized by gene expression analysis (38). With proteomics we can also identify which proteins 
interact, which can give important clues about the functions of newly discovered proteins. One of the 
most important outcomes from the study of genes and proteins has been the identification of 
potential new drugs for the treatment of disease. Also, understanding the structure and function of 
protein-protein interactions is important for the development of effective diagnostic techniques and 
disease treatments. Proteomics can be used to identify proteins produced during a particular disease, 
which can be used to diagnose the disease quickly (76).  
 
Various technologies are used for proteomics which include, one- and two-dimensional gel 
electrophoresis (used to identify the isoelectric point of a protein as well as its relative mass) (9); 
mass spectrometry, example MALDI-TOF (is used to identify proteins by peptide mass 
fingerprinting) (37); Affinity chromatography, yeast two hybrid techniques (used to identify protein-
protein and protein-DNA binding reactions) (6); software based image analysis (used to automate 
the quantification and detection of spots within and among gels samples) (74). 
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2.5.4 QT-PCR analysis  
Quantitative reverse transcriptase polymerase chain reaction (QT-PCR) can be used to measure gene 
expression of candidate genes identified by whole genome sequencing and microarray analysis. The 
level of differential expression between two different M. tuberculosis strains can be measured (33). 
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2.6 SUMMARY 
 
The models described in this review were very important to better our understanding of the very 
successful bacterium, Mycobacterium tuberculosis, which is responsible for so many deaths each 
year. Each one of the models has certain advantages as well as limitations, but all of them 
contributed in their own unique way to further our knowledge of TB and the causative agent, but 
as we have seen, one specific model does not give the answer to all the questions, therefore a 
combination of the different types of models is needed. Some of the tissue culture models contain 
human cells. Therefore these models might give a better representation of the immune and other 
physiological responses encountered in the human when infected with the bacterium, than what is 
encountered in an animal model. However, some of these tissue culture models are monolayered, 
and in vitro tissue culture models are artificial and do not represent the complex interactions that 
occur in humans or animals. Therefore the knowledge gained from tissue culture research have to 
be used in conjunction with that gained from animal studies to give a better understanding of the 
host-pathogen interactions. Transmission, which can be used as an indicator of strain virulence or 
fitness, is difficult to study in tissue culture models or animal models; therefore molecular 
epidemiological techniques are used to study transmissible clinical M. tuberculosis isolates. There 
are many different molecular techniques available today, which leads to new information about M. 
tuberculosis, and its host, as well as other factors that might play a role in the pathogen’s success 
that are contributing to our knowledge and understanding of the TB disease. There are also very 
exciting new models that are being investigated. These include Dictyostelium discoideum (64), 
which is used as a surrogate macrophage, Caenorhabditus elegans and Drosphila melanogaster are 
being investigated as TB hosts to study conserved innate immune mechanisms (64), and the 
zebrafish is used to study both innate and adaptive immunity (64,82). These models were 
developed as model hosts to study aspects of TB that cannot be studied in the mouse model. 
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Table 2.1. Methods currently used to study the molecular epidemiology of TB. 
 
 
METHOD ADVANTAGES DISADVANTAGES 
RFLP (87)  
Gold standard Labour intensive 
Widely used - much data available for comparison Requires sub-culturing and DNA isolation 
Marker stability very adequate for the study of 
transmission  Time consuming 
Extensive diversity in patterns for isolates with 
more than 6 IS6110 insertions 
Cannot be used to reliably type isolates with less than 
 6 IS6110 insertions 
Mixed infections can readily be detected Cannot be used to type strains with no IS6110 insertions  
Can also be used for evolutionary and phylogenetic 
studies Interlaboratory comparative analysis can be difficult 
Laboratory error/cross-contamination can be 
detected   
Spoligotyping 
(41) 
Very simple and easy technique Less discriminatory then IS6110 RFLP genotyping 
No DNA purification required, can perform 
directly on cell lysate   
Can be performed on non-viable bacteria   
Standardized analysis for 43 spacers   
Hybridization membranes for simultaneous 
analysis of 40-45 samples commercially available   
Data can be presented in binary format, allowing 
inter- and intralaboratory comparisons   
Two large databases available for comparative 
analysis   
MIRU-
VNTR (58)  
Rapid, high-throughput technique Less discriminatory then IS6110 RFLP genotyping 
Can be performed directly on cell lysate, no DNA 
purification required Similar patterns may be found in distinct lineages 
Digitized results   
Suited for large-scale genotyping   
Manual as well as automated analysis is possible   
SNP (43) 
Most precise information on strains based on 
sequencing of polymorphic loci 
Requires extensive genome sequencing of multiple  
chromosome targets 
High resolution   
Some selected SNP can be highly informative   
Can be automated for large-scale genotyping   
Other applications include phylogenetic analysis, 
drug-resistant studies, research on host-pathogen 
interactions 
  
Genomic 
deletion 
analysis (86) 
High throughput unit microarray analysis Not yet standardized  
Reserve line probe with hybridization membrane 
possible Representative target deletions need to be determined 
Results can be digitalized Technique has yet to be evaluated in different settings 
Multiplex PCR for 43 loci available    
Other applications include phylogenetic analysis, 
host-pathogen interactions based on specific 
genomic deletions, facilitation of genome 
structure-function studies 
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CHAPTER 3 
 
 
 
 
SPREAD OF A LOW FITNESS DRUG-RESISTANT MYCOBACTERIUM 
TUBERCULOSIS STRAIN IN A SETTING OF HIGH HIV PREVALENCE. 
 
 
 
 
 
My contribution to this project: 
Study design 
Drug resistance genotyping 
Spoligotyping 
Interpretation of data 
Writing of manuscript 
 
 
 
The results from this study were written up in the form of a note and were recently submitted 
(October 2007) to the Journal of Clinical Microbiology. 
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3.1 BACKGROUND 
 
The fitness of M. tuberculosis strains circulating in a community is thought to be the driving force 
perpetuating the TB epidemic. This is particularly true for the spread of drug resistance, as dogma 
has suggested that the evolution of drug resistance has a fitness cost resulting in the overall 
attenuation of the pathogen (1). This phenomenon has been demonstrated during the spontaneous 
evolution of rifampicin (RIF) resistance, where a direct correlation was observed between the 
frequency at which a specific non-synonymous single nucleotide polymorphism (nsSNP) occurred 
and the fitness of the mutant clone (4). That study suggested that rarely observed nsSNPs had a high 
fitness cost, while frequently observed nsSNPs had a low fitness cost. These results correlated well 
with the frequency of nsSNPs observed in RIF-resistant clinical isolates (4). However, it was not 
clear whether the genetic background of the clinical isolates with high fitness cost nsSNPs had 
influenced their ability to spread and cause disease (4).  
 
Molecular studies have suggested that certain M. tuberculosis strains are epidemiological more 
successful than others (3). This has been demonstrated by the spread of strains from the Beijing 
strain family in most settings world-wide (5). Accordingly, it has been hypothesized that this is a 
high fitness genotype, possibly as a result of the evolution of unique properties, including the ability 
to evade the protective effect of BCG vaccination (15), the ability to spread more readily (2) and the 
ability to acquire drug-resistance more frequently (11).  
 
Analysis of the NTF region of the genome has demonstrated that strains with the Beijing genotype 
can be broadly grouped as typical or atypical according the presence or absence of an IS6110 
insertion in this region, respectively (9). Phylogenetic analysis has provided evidence that these two 
genotypes are derived from a common progenitor (6). However, they demonstrate vastly different 
epidemiological characteristics as strains with the atypical Beijing genotype are only rarely 
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observed (9,13). This has prompted speculation that atypical Beijing strains are of a lower fitness as 
compared to typical Beijing strains. Thus we hypothesize that high fitness cost RIF resistance 
causing nsSNPs would only be rarely observed in M. tuberculosis strains with an atypical Beijing 
genotype unless epidemiological factors favouring their spread were present.  
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3.2 MATERIALS AND METHODS 
 
STUDY DESIGN (The different techniques used in this study are described in detail in Chapter 5.) 
To test this hypothesis, sputum specimens were collected from re-treatment cases attending health-
care clinics or TB referral hospitals in two regions in SA. Each specimen was subjected to routine 
culture-based drug-susceptibility testing for isoniazid and rifampicin. To identify the nsSNPs 
conferring RIF resistance, the RRDR of the rpoB gene (12) of the first isolate from each patient was 
subjected to DNA sequencing. In order to determine whether a relationship existed between strain 
genotype and the fitness cost of the respective nsSNPs, the isolates from this study were classified 
as either Beijing or non-Beijing by spoligotyping (8). IS6110 DNA fingerprinting (14) was also 
done to determine whether the Beijing isolates associated with specific nsSNPs were transmitted. 
Determination of the regions of difference of the M. tuberculosis isolates was done using a PCR-
based method. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Experimental design of this study. INH=isoniazid; RIF=rifampicin; RFLP=restriction 
fragment length polymorphism; RD=region of difference. 
Re-treatment cases  
 
(1) Decontaminated and liquefied 
 
(2) BACTEC mini-cultures 
DRUG SUSCEPTIBILITY TESTING 
(INH, RIF) 
DRUG RESISTANCE GENOTYPING 
(rpoB, katG, inhA Promoter) 
DNA FINGERPRINTING 
Spoligotyping, IS6110 RFLP, RD 
WESTERN CAPE 
312 sputum samples 
(January 2001 – October 2004) 
EASTERN CAPE 
117 sputum samples 
(September 2003 – May 2004) 
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3.3 RESULTS AND DISCUSSION 
 
Sequence analysis showed that >90% of RIF-resistant isolates had a nsSNP in the RRDR region of 
the rpoB gene. Of the 30 nsSNPs identified, 25 nsSNPs appeared at a frequency consistent with 
frequencies reported in in vitro generated rifampicin-resistant mutants (4,7,10) (Table 3.1). 
However, the frequency of appearance of the remaining 5 nsSNPs was discordant when compared 
to the in vitro generated rifampicin-resistant mutants (Table 3.1). The nsSNPs at codons 516 
(GACGTC) and (GACTAC) and 533 (CTGCCG) were significantly over-represented in the 
rifampicin-resistant clinical isolates, while nsSNPs at codon 522 (CTGCCG) and codon 526 
(CTGCCG) were significantly under-represented (Table 3.1). This suggests that the two nsSNPs 
at codon 516 had a lower high fitness cost in clinical TB as compared to in vitro generated 
rifampicin-resistant mutants. Conversely, the nsSNPs at codons 522 (CTGCCG) and 526 
(CTGCCG) appear to have a high fitness cost in clinical TB. 
 
In order to determine whether a relationship existed between strain genotype and the nsSNPs 
conferring rifampicin-resistance, the isolates from this study were classified as either Beijing or 
non-Beijing by spoligotyping (8). The results showed that 116 (37%) of the rifampicin-resistant 
cases from the WC region and 59 (50%) of the rifampicin-resistant cases from the EC region were 
infected with a Beijing genotype strain, respectively (Table 3.1). Sub-classification of the Beijing 
isolates as either typical or atypical (6) showed that the population structure of rifampicin-resistant 
Beijing strains was significantly different in the two study settings [Fisher’s exact test OR = 21.6; 
CI95% 9.6 to 48.6, p<0.0001] (Table 3.1). The nsSNP at codon 516 (GACGTC) was associated 
with the atypical Beijing genotype from the EC [Fisher’s exact test OR = 45; CI95% 3.8 to 525, 
p=0.0008], while the nsSNP at codon 533 was mostly found in isolates with the typical Beijing 
genotype from the WC (Table 3.1). 
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IS6110 DNA fingerprinting (14) was done to determine whether the Beijing isolates with nsSNPs at 
codons 516 (GACGTC) and 533 (CTGCCG) were transmitted. Analysis of these DNA 
fingerprints showed that isolates from the WC region with the typical Beijing genotype and either 
an nsSNP at codon 516 or codon 533 were not clustered, thereby suggesting that these nsSNPs had 
evolved independently and that the resulting clones were not transmitted.  In contrast, the isolates 
from the EC region with the atypical Beijing genotype and an nsSNP at codon 516 (GACGTC) 
were clustered and also shared the rare -17 inhA promoter mutation (GACTAC) (data not 
shown), suggesting ongoing transmission. The above isolates were also clustered with the atypical 
Beijing strains from the WC which had an nsSNP at codon 516 (GACGTC) and the -17 inhA 
promoter mutation, suggesting inter-provincial spread. This finding is contrary to previous reports 
which have suggested that atypical Beijing strains are attenuated in their ability to transmit (9,13), 
while the mutation at codon 516 (GACGTC) would have been expected to further compromise 
the ability of these strains to transmit unless compensatory mutations were present or the 
epidemiological context allowed transmission to occur. Analysis of the host population in the EC 
region showed HIV co-infection to be a risk factor for the spread of the atypical Beijing strains [z-
test for the hypothesis that proportion of HIV + cases = 0.42, p=0.029]. In contrast, the frequency of 
atypical Beijing strains was low in the WC region which in turn has a low incidence of HIV/TB co-
infection (6). This raises concern for the spread of all drug-resistant strains in vulnerable 
populations.  
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3.4 CONCLUSION 
 
The fitness cost associated with the evolution of rifampicin-resistance in Mycobacterium 
tuberculosis may be different in clinical tuberculosis as compared to in vitro generated mutants. The 
results from this study are very alarming. An atypical Beijing strain (attenuated phenotype) 
demonstrated the ability to spread despite acquiring rifampicin-resistance. This atypical Beijing 
strain has an rpoB mutation at codon 516 that are not frequently seen in in vitro generated rpoB 
mutants and is not dominant in clinical isolates, and are therefore thought to be a high fitness cost 
mutation. HIV co-infection could be linked to this specific strain [p=0.029] and might be the reason 
for its spread; therefore, greater vigilance is required to contain the drug-resistant TB epidemic in 
high HIV prevalence settings. This can be achieved by the development and implementation of 
rapid diagnostics, provision of appropriate therapy, ensuring treatment adherence and intensified 
screening of contacts. However, in order for diagnosis and treatment to be effective it is essential 
that communities are educated to improve health seeking behaviour.  
 
 
60 
 
3.5 
 
Reference List 
 
 1.  Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical 
conclusions? Curr.Opin.Microbiol. 9:461-465. 
 2.  Bifani, P. J., B. Mathema, N. E. Kurepina, and B. N. Kreiswirth. 2002. Global 
dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 
10:45-52. 
 3.  European Concerted Action on New Generation Genetic Markers and Techniques for 
the Epidemiology and Control of Tuberculosis. 2006. Beijing/W genotype Mycobacterium 
tuberculosis and drug resistance. Emerg.Infect.Dis. 12:736-743. 
 4.  Gagneux, S., C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J. Bohannan. 
2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 
312:1944-1946. 
 5.  Glynn, J. R., J. Whiteley, P. J. Bifani, K. Kremer, and D. van Soolingen. 2002. 
Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic 
review. Emerg.Infect.Dis. 8:843-849. 
 6.  Hanekom, M., G. D. van der Spuy, E. Streicher, S. L. Ndabambi, C. R. McEvoy, M. 
Kidd, N. Beyers, T. C. Victor, P. D. van Helden, and R. M. Warren. 2007. A recently 
evolved sublineage of the Mycobacterium tuberculosis Beijing strain family was associated 
with an increased ability to spread and cause disease. J.Clin.Microbiol.  
 7.  Huitric, E., J. Werngren, P. Jureen, and S. Hoffner. 2006. Resistance levels and rpoB gene 
mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. 
Antimicrob.Agents Chemother. 50:2860-2862. 
 8.  Kamerbeek, J., L. Schouls, A. Kolk, M. van Agterveld, D. van Soolingen, S. Kuijper, A. 
Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. Van Embden. 1997. Simultaneous 
detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and 
epidemiology. J.Clin.Microbiol. 35:907-914. 
 9.  Mokrousov, I., O. Narvskaya, T. Otten, A. Vyazovaya, E. Limeschenko, L. Steklova, and 
B. Vyshnevskyi. 2002. Phylogenetic reconstruction within Mycobacterium tuberculosis 
Beijing genotype in northwestern Russia. Res.Microbiol. 153:629-637. 
 10.  Morlock, G. P., B. B. Plikaytis, and J. T. Crawford. 2000. Characterization of spontaneous, 
In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. 
Antimicrob.Agents Chemother. 44:3298-3301. 
 11.  Rad, M. E., P. Bifani, C. Martin, K. Kremer, S. Samper, J. Rauzier, B. Kreiswirth, J. 
Blazquez, M. Jouan, D. van Soolingen, and B. Gicquel. 2003. Mutations in putative 
mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. 
Emerg.Infect.Dis. 9:838-845. 
61 
 
 12.  Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. 
Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in 
Mycobacterium tuberculosis. Lancet 341:647-650. 
 13.  Toungoussova, O. S., A. Mariandyshev, G. Bjune, P. Sandven, and D. A. Caugant. 2003. 
Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the 
Archangel prison in Russia: predominance of the W-Beijing clone family. Clin.Infect.Dis. 
37:665-672. 
 14.  van Embden, J. D., M. D. Cave, J. T. Crawford, J. W. Dale, K. D. Eisenach, B. Gicquel, 
P. Hermans, C. Martin, R. McAdam, and T. M. Shinnick. 1993. Strain identification of 
Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized 
methodology [see comments]. J.Clin.Microbiol. 31:406-409. 
 15.  van Soolingen, D., L. Qian, P. E. de Haas, J. T. Douglas, H. Traore, F. Portaels, H. Z. 
Qing, D. Enkhsaikan, P. Nymadawa, and J. D. van Embden. 1995. Predominance of a 
single genotype of Mycobacterium tuberculosis in countries of east Asia. J.Clin.Microbiol. 
33:3234-3238. 
 
62 
 
Table 3.1. Distribution of mutations conferring RIF resistance in clinical isolates from the 
Western and Eastern Cape regions of South Africa. 
 
  
rpoB codon 
  
In vitro RIFR 
mutantsa 
(n=304) 
  
Fitness 
costb 
Western Cape region Eastern Cape region 
All RIFR 
cases 
(n=312) 
Beijing RIFR cases 
(n=116) All RIF
R 
cases 
(n=117) 
Beijing RIFR cases 
(n=59) 
Typical 
(n=101) 
Atypical 
(n=15) 
Typical 
(n=14) 
Atypical 
(n=45) 
490  high 1      
511  high 3 2 1 3 3  
512  high 3      
513 8 high 5  1    
516 3 high 32 7 4 35 2 30 
519 1 high       
522 37 low       
526 110 low 39 8 1 8 2 2 
529 2 high       
531 123 low 181 61 8 60 5 11 
533 1 high 17 12     
Multiple nsSNPs 2 high 1      
Insertions 1 high 1      
Deletions 15c  2      
nsSNPs absent 
from RRDR 1 high 27 11   11 2 2 
Legend to Table 3.1: 
a Combined data from (4,7,10) 
b Assigned according to the definition described in (4) 
c Eleven different deletion events (7,10) 
RIFR = rifampicin-resistant, RRDR = rifampicin resistance determining region. 
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CHAPTER 4 
 
 
 
PROTEIN EXPRESSION PROFILES OF LARGE, SMALL, AND ATYPICAL 
DRUG-RESISTANT CLUSTERS OF THE BEIJING STRAIN FAMILY. 
 
 
 
 
 
 
 
 
My contribution to this project: 
Planning of project 
Strain culture and growth 
Protein isolation 
2-D gel electrophoresis 
Data analysis 
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4.1 BACKGROUND 
 
Previous studies have shown that the drug-resistant TB epidemic in SA is driven predominantly by 
transmission of M. tuberculosis strains (5,7,10,11,13-15). Evident from these studies was that certain 
family specific drug-resistant strains from within the same strain family have a higher propensity to 
transmit, despite the maintenance of a constant control program and a stable community (Figure 
4.1). The definition that was assigned to a strain family was that the strains have to have ≥65% 
IS6110 RFLP banding pattern similarity. Those strains could be grouped into clusters according to 
DNA fingerprints (with identical or similar IS6110 RFLP fingerprints, and similar or identical 
spoligotype patterns) and drug resistance conferring mutations in different genes associated with 
drug resistance (e.g. rpoB (RIF resistance) (6), katG (INH resistance) (4), inhA promoter gene (INH 
resistance) (4)). The Beijing strain family was one of the largest strain families identified in the 
longitudinal reference database representing 31% of all the drug-resistant strains, and could be 
divided into large (>10 isolates with identical or near identical genotypic characteristics) and small 
clusters (2-5 isolates with identical or near identical genotypic characteristics). The Beijing strain 
family can broadly be grouped into typical and atypical according to the presence or absence of an 
IS6110 insertion in the NTF region (8). It has been speculated that the typical Beijing strains are 
hyper mutable and therefore have an increased ability to develop drug resistance, and are able to 
spread more readily (2,9). Defects in DNA repair genes are unique to the typical Beijing strains and 
it has been proposed that this may partly explain the high prevalence of typical Beijing drug-resistant 
strains (9). In contrast, the atypical Beijing strains are not frequently associated with drug resistance, 
are rarely observed, and are thought to be attenuated in their ability to transmit (8,12). In this study, 
the typical Beijing strain is Beijing cluster 220, which is a dominant cluster representing 42% of the 
Beijing drug-resistant isolates in a region in the Western Cape province of South Africa called the 
Boland-Overberg-Karoo-Southern Cape (BOKS) region, and was responsible for an outbreak in a 
high school in Cape Town in 2005 (7). All cluster 220 strains identified in this region have a -15 
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inhA (C→T) promoter mutation, and no drug-susceptible Beijing Cluster 220 isolate has been 
identified yet (Johnson R et al. - manuscript in preparation). Our observations showed that this strain 
is highly transmissible and therefore very fit, but we also observed other drug-resistant strain 
clusters, within the Beijing strain family, that consist of only one or two isolates per cluster. This is 
puzzling, since they also belong to this highly successful Beijing strain family, but are less 
transmitted and therefore implying that they are less fit. 
 
In this study we aim to understand on a proteomic level, why specific drug-resistant M. tuberculosis 
strains like Beijing Cluster 220, transmit better than other drug-resistant strains from the same strain 
family, under a constant TB control programme and a stable community. We also aim to understand 
what the proteomic differences are between the typical Beijing strain (regarded as more fit) and the 
atypical Beijing strain (Chapter 3), which is regarded as less fit.  
 
 
4.2 Problem statement 
We have previously found that certain family specific drug-resistant M. tuberculosis strains within 
the same strain family have a higher propensity to transmit, despite the maintenance of a constant 
TB control program and a stable community (Figure 4.1). This suggests that the strain dynamics 
within a strain family are not the same. 
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Figure 4.1. The figure illustrates the TB phenomenon that is seen in different settings in SA. The arrows illustrate that 
certain clusters (specifically the smaller clusters) can be stopped by the TB control programme, whereas some of the 
large clusters (indicated by darker arrows) cannot be controlled. Examples of large clusters that were responsible for 
drug-resistant TB outbreaks in different regions in SA include Beijing Cluster 220 (7), LCC (Low Copy Clade) DRF150 
(Drug-resistant Family 150) (15), LCC F140 (Family 140) (Manuscript in preparation), and Atypical Beijing F31 
(Family 31) (this thesis, Chapter 3) 
 
Hypothesis 
Differential expression of proteins in Beijing drug-resistant strains will aid in the identification of 
proteins that allow certain strains to transmit more than others. 
 
Aim 
To make use of 2-D gel electrophoresis in order to determine whether the transcriptome between a 
large and small Beijing cluster, as well as a typical and atypical Beijing cluster, is differentially 
expressed.  
Community Community TB control 
program 
Cluster 
220 
Beijing 
 
BOKS; 
PE F31       (rpoB 516) 
LCC 
 
BOKS 
DRF 150 
LCC 
 
Gold 
mines 
F140 
Cluster 
213 
Beijing 
 
R/U 
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4.3 MATERIALS AND METHODS 
 
The different methods as well as the buffers and solutions used in this study are described in detail in 
Chapter 6. 
 
STUDY DESIGN 
 
Strain selection 
A laboratory H37Rv strain and a representative dug-resistant M. tuberculosis clinical isolate from a 
large (Cluster 220), small (Cluster 6018), and atypical Beijing cluster were selected from a 
longitudinal reference database maintained at the University of Stellenbosch. The criteria used for 
therefore strain selection was as follows: i) the two strains from the large and small Beijing clusters 
had to be drug-resistant (at least MDR); ii) the strains had to be collected at the same time period, so 
that it could be determined whether both strains had equal opportunity to transmit; iii) additional 
confounding factors, such as patient compliance were also taken into account in the selection of 
these strains.; iv) an atypical strain, which did not necessarily fit above criteria, was also selected to 
compare its protein expression profile to that of a typical Beijing strain. 
 
M. tuberculosis culture conditions 
The strains were grown on LJ slants with continuous aeration for approximately three weeks. After 
three weeks, colonies were scraped from the LJ slants and inoculated into 20ml 7H9 Middlebrook 
medium and incubated at 37°C without shaking, until an OD600 of 0.6-0.8 was reached. Whole cell 
lysate (WCL) proteins were extracted and the concentrations of the proteins were determined using 
the Bradford assay (3). The proteins were purified using the ReadyPrep 2-D CleanUp Kit and 
subsequent protein concentrations were determined using the RC DC Protein assay. 
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2-D Gel Electrophoresis 
 
The WCL proteins were prepared for isoelectric focusing (IEF) where proteins were separated 
according to pH, after which 2-D gel electrophoresis was done as described (1), with minor changes 
described in detail in Chapter 5. In this study, the 2-D gels were stained with silver stain compatible 
with mass spectrometry. The gels were then scanned and recorded using a GS-800 Calibrated 
Densitometer (Bio-Rad Laboratories). Detection of differentially expressed protein spots was done 
using Quantityone and PDQuest (Bio-Rad) software, together with careful visual inspection. After 
the 2-D gels (two duplicate gels for each strain) were scanned into the computer, PDQuest created a 
master gel, which is a combination of all 4 gels; all protein spots are therefore visible on the master 
gel. Using this master gel, the computer then measured the intensity of each spot in the 2-D gels of 
one strain and compared it to the spots in the 2-D gels of the other strain to see which proteins are 
present or absent in the two strains or which proteins are up or down regulated according to spot 
intensities (larger spots mean proteins are up regulated and if the spot is smaller it means the protein 
is down regulated). 
 
Differentially expressed proteins were excised and stored in milliQH2O for future mass 
spectrometric analyses. Due to time constraints mass spectrometric analyses could not be done for 
this study. Figure 2 gives a diagrammatic illustration of the study design. 
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Figure 4.2. A diagrammatic illustration of the study design. 
Legend to Figure 4.2: WCL=whole cell lysate; 1-D=1 dimensional; 2-D=2 dimensional. 
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4.4 RESULTS 
 
Table 4.1 shows the characteristics of the large, small, and atypical clusters from the Beijing strain 
family that were investigated in this study. To make a comparison between the protein expression 
profiles of the large and small Beijing clusters, both strains fit the criteria mentioned under study 
design. Both strains were at least resistant to INH and RIF, both strains were collected from the same 
time period (between February 2001 and February 2002), and both the patients from which the 
strains were collected originated from the same town and clinic in the Southern Cape region, which 
is in the WC province of SA. The red arrows in Table 4.1 indicate the differences between the 
IS6110 RFLP fingerprints of the large and small Beijing clusters. The IS6110 RFLP fingerprint of 
the atypical Beijing strain is also different from both the other two typical Beijing strains 
(differences indicated by the red arrows in Table 4.1).  
 
Table 4.1. Characteristics of the small, large and atypical Beijing clusters. 
Strain Drug resistance phenotype IS6110 RFLP pattern 
Beijing Cluster 220 
(large cluster) 
 
n=148/362 – all drug-resistant 
Beijing isolates from BOKS 
 
H,R,E,S,Et,Thia 
 
Beijing Cluster 6018 
(small cluster) 
 
n=2/362 - all drug-resistant 
Beijing isolates from BOKS 
 
H,R,Z,S 
 
Atypical Beijing 
 
n=45/59 all drug-resistant 
atypical Beijing isolates 
from the EC 
sample collection 
 
H,R 
 
 
Legend to Table 4.1: 
RFLP=restriction fragment length polymorphism; H=isoniazid; R=rifampicin; E=ethambitol; S=streptomycin; 
Et=ethionamide; Thia=thiacetazone; Z=pyrizinamide; BOKS=Boland-Overberg-Karoo-Southern Cape; EC=Eastern 
Cape province. 
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In figure 4.3, each differentially expressed spot is reviewed independently. Figure 4.3A, represents 
the master gel. Figures 4.3B and 4.3C represents two duplicate gels of the large Beijing cluster. 
Figures 4.3D and 4.3E represents two duplicate gels of the small Beijing cluster. Figure 4.3F, 
represents one spot (SSP2002) that is present in the small Beijing cluster (black squares) but absent 
in the large Beijing cluster (black circles). The green bars represent the two duplicate gels from the 
small Beijing cluster indicating that spot 2002 is present and no bars are shown for the large Beijing 
cluster indicating that spot 2002 is absent.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Reviewing of differentially expressed protein spots using the Spot Review Tool. Figure 4.3A, represents the 
master gel which is a combination of all the gels, all protein spots are therefore visible on the master gel, figures 4.3B 
and 4.3C represents two duplicate gels of the large Beijing cluster. Figures 4.3D and 4.3E represents two duplicate gels 
of the small Beijing cluster. Figure 4.3F, represents one spot (SSP2002) that is present in the small Beijing cluster (black 
squares) but absent in the large Beijing cluster (black circles). The green bars represent the two duplicate gels from the 
small Beijing cluster indicating that spot 2002 is present and no bars are shown for the large Beijing cluster indicating 
that spot 2002 is absent.  
D 
B 
Duplicate gels of the small Beijing cluster 
Duplicate gels of the large Beijing cluster Master gel 
A C 
E F 
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Figures 4.4, 4.6, and 4.8, show the electrophoretic fractionation of WCL proteins in 2-D silver-
stained gels (pI range of pH 4-7, with a molecular weight of 10-100 kDa). Each differentially 
expressed protein has a significant p value of < 0.05. The p value was determined using a PDQuest 
integrated statistical analysis tool, T-test, with confidence interval of 95%. Comparison of protein 
expression between the large and small clusters by PDQuest analysis showed approximately 120 
distinct protein spots (Figure 4.4), of which 64 were significantly differentially expressed (p=0.05) 
between the two strains (Table 2). Figure 4.5, shows a representation of a few differentially 
expressed proteins between the two different clusters. Twelve (12) proteins were absent in the large 
Beijing cluster and present in the small Beijing cluster, and 11 proteins were absent in the small 
Beijing cluster but present in the large Beijing cluster. Furthermore, 24 proteins were down regulated 
in the large Beijing cluster, but were up regulated in the small Beijing cluster, and 17 proteins were 
up regulated in the large Beijing cluster but down regulated in the small Beijing cluster.  
 
 
 
 
 
 
 
 
 
Figure 4.4. Examples of the 2-D protein gels showing protein spots of the large and small Beijing clusters used in this 
study. A=small Beijing cluster; B=large Beijing cluster. The red arrows indicate some of the protein spots that were 
different between the two clusters. 
Large Beijing cluster 
pH 4 7 MW kDa 
Small Beijing cluster 
pH 4 7 MW kDa 
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Figure 4.5. A representation of a few differentially expressed proteins (including proteins that are present or 
absent), between the large and small Beijing clusters. 
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Table 4.2. Differentially expressed protein spots between Beijing cluster 220 (large cluster) and 
Beijing cluster 6018 (small cluster). 
Protein spots Large cluster 
Small 
cluster Ratio 
SSP number     
10 - 11.1 18.56 
101 13.6 50.9 3.37 
104 - 28 46.75 
402 - 23.8 39.63 
501 25.4 73.6 2.9 
503 - 47.5 79.25 
1003 - 77.2 128.85 
1201 23 36.6 1.59 
1701 87.7 125.1 1.43 
1801 22.5 35.8 1.6 
1905 - 123 20.56 
2001 - 131.5 219.47 
2002 - 75.4 125.72 
2102 - 18.3 30.58 
2602 49.9 66.6 1.33 
2701 23.7 34.6 1.46 
2801 14 20 1.43 
2804 29.7 66.6 2.24 
3003 195.3 60.8 0.31 
3203 11.4 - 0.13 
3602 50.7 89.9 1.77 
3603 48.9 - 1.77 
3604 40.5 105.8 2.61 
3701 45.5 167.9 3.69 
3901 15.1 50.7 3.35 
4101 96.6 43.6 0.45 
4201 81.6 24.4 0.3 
4302 48 35 0.73 
4501 22.2 - 0.07 
4603 123.7 101.8 0.82 
4605 - 39 65.04 
4802 11 - 0.14 
4903 22.2 50.9 2.29 
5302 119.3 84.2 0.71 
5403 79.3 49.3 0.62 
5404 112.5 20.6 0.18 
5601 34.2 19.6 0.57 
5605 13.4 43.7 3.27 
5701 251.2 158 0.63 
5702 65.1 95 1.46 
5703 - 19.5 32.57 
5802 32 68.1 2.13 
5803 19.2 - 0.08 
5804 16.6 42.3 2.54 
6001 60.1 96.1 1.6 
6203 27.4 - 0.06 
6501 41.5 28.9 0.7 
6502 29.8 - 0.05 
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6602 86.1 61.3 0.71 
6605 14.7 - 0.1 
6704 76.2 60.9 0.8 
6707 - 78.5 131.02 
6802 18.5 7.3 0.4 
7101 60.5 - 0.02 
7103 59.4 - 0.03 
7301 19.4 - 0.08 
7304 33.9 15.4 0.45 
7502 82.5 44.8 0.54 
7703 76.9 62.2 0.81 
8001 64.8 32.4 0.5 
8101 80.5 12.5 0.16 
8302 26.7 21 0.79 
8801 12.8 28.7 2.25 
9603 68.6 113.8 1.66 
 
Legend to Table 4.2: 
MW = molecular weight; pI = pH range; SSP number = the number that the computer assign to the protein spots; - = 
protein absent. 
 
Comparison of protein expression between the large typical Beijing cluster and the atypical Beijing 
strain showed 260 distinct protein spots, of which 59 were significantly differentially expressed 
between the two strains (p=0.05) (Table 3). Figure 4.7, shows a representation of a few differentially 
expressed proteins between the two different clusters. Ten (10) proteins were absent in the large 
typical Beijing cluster and present in the atypical Beijing cluster, and 6 proteins were absent in the 
atypical Beijing cluster but present in the large typical Beijing cluster. Furthermore, 26 proteins were 
down regulated in the large typical Beijing cluster, but were up regulated in the atypical Beijing 
cluster, and 17 proteins were up regulated in the large typical Beijing cluster but down regulated in 
the atypical Beijing cluster.  
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Figure 4.6. Comparison between 2D protein gels from a typical Beijing strain (large cluster) and the atypical Beijing 
strain. The red arrows indicate some of the differential protein spots between the two strains. 
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Figure 4.7. A representation of a few differentially expressed proteins (including proteins that are present or 
absent), between the large and atypical Beijing clusters. 
Atypical Beijing 
pH 4 7 MW kDa 
Large Beijing cluster 
pH 4 7 MW kDa 
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Table 4.3. Differentially expressed protein spots between Beijing cluster 220 (large cluster) and the 
atypical Beijing strain. 
 
Protein spots Large cluster Atypical cluster Ratio 
SSP number     
1 59.5 116.8 0.51 
101 25.3 46.2 0.32 
302 - 56.6 0.01 
303 - 23.7 0.02 
306 30.9 - 37.3 
402 - 44.5 0.01 
501 16.6 48.7 0.34 
603 35.6 150 0.24 
701 - 28.2 0.01 
801 19.2 59.6 0.32 
1301 133.3 647.8 0.21 
1303 - 39.3 0.01 
1401 119.6 160.8 0.74 
1601 78 112.8 0.69 
1701 64.8 144.2 0.45 
1801 14.1 35.3 0.4 
1906 21 48.2 0.44 
2002 - 69.9 0.01 
2103 48.4 97.8 0.49 
2201 - 38.6 0.01 
2501 71.4 206.9 0.35 
2602 31.8 46.6 0.68 
2702 100.5 48.7 2.06 
2802 26.3 17.4 1.51 
3002 113.1 116.6 0.97 
3705 36.8 - 44.33 
3706 32.5 9.2 3.54 
3801 62.9 22.1 2.84 
3802 23 12.3 1.86 
4302 68.9 - 83.12 
4802 78.5 51.6 1.52 
4902 31.9 34.2 0.93 
5301 29.8 52.2 0.57 
5403 91.8 30.9 2.97 
5501 39.3 19.4 2.03 
5703 117.2 38.3 3.06 
5902 15.2 - 18.37 
6303 - 17.4 0.02 
6602 61.3 - 73.89 
6703 57.2 - 68.98 
7001 38.1 10.3 3.69 
7303 12.1 26.8 0.45 
7401 34.8 100.4 0.35 
7501 25.9 39.3 0.66 
7503 31.4 36.2 0.87 
7601 50.1 33.2 1.51 
7605 16.5 10.5 1.57 
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8201 45.1 102.9 0.44 
8303 21.2 31.4 0.67 
8701 49.8 32.3 1.54 
9001 52.2 29 1.8 
9101 57 34.5 1.65 
9103 95.9 77 1.25 
9104 - 46.7 0.01 
9105 - 78 0.05 
9303 24.2 49.3 0.49 
9402 62.4 13.7 4.54 
9501 32.9 68.2 0.48 
9503 70.7 147.2 0.48 
 
Legend to Table 4.3: 
MW = molecular weight; pI = pH range; SSP number = the number that the computer assign to the protein spots; - = 
protein absent. 
 
 
Comparison of protein expression between the small Beijing cluster and the atypical Beijing strain 
showed approximately 293 distinct protein spots, of which 132 were differentially expressed 
(p=0.05) between the two strains (Table 4). Figure 4.9, shows a representation of a few differentially 
expressed proteins between the two different clusters. Eighteen (18) proteins were absent in the 
small typical Beijing cluster and present in the atypical Beijing cluster, and 11 proteins were absent 
in the atypical Beijing cluster but present in the small typical Beijing cluster. Furthermore, 50 
proteins were down regulated in the small typical Beijing cluster, but were up regulated in the 
atypical Beijing cluster, and 53 proteins were up regulated in the small typical Beijing cluster but 
down regulated in the atypical Beijing cluster.  
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Figure 4.8. Comparison between 2D protein gels from a typical Beijing strain (small cluster) and the atypical Beijing 
strain. The red arrows indicate some of the differential protein spots between the two strains. 
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Figure 4.9. A representation of a few differentially expressed proteins (including proteins that are present or 
absent), between the small Beijing cluster and atypical Beijing strain. 
Small Beijing cluster 
pH 4 7 MW kDa 
Atypical Beijing 
pH 4 7 MW kDa 
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Table 4.4. Differentially expressed protein spots between Beijing cluster 6018 (small cluster) and 
the atypical Beijing strain. 
Protein spots Small cluster Atypical cluster Ratio 
SSP number      
1 97.2 128.9 1.33 
2 475.5 - 0 
102 27.9 19.1 0.68 
103 70.3 25.5 0.63 
104 17.5 48.3 2.77 
105 28.8 56.1 1.95 
301 26.1 73 2.8 
401 21.6 119.3 5.51 
503 63.5 19.1 0.3 
504 108 153.9 1.43 
1001 67 104.4 1.56 
1101 21.9 - 0.07 
1201 33.2 25.3 0.76 
1203 29.9 21.2 0.71 
1401 57.7 218.2 3.78 
1406 119.1 203.6 1.71 
1407 142.4 60 0.42 
1502 177.2 93.8 0.53 
1503 41.2 23.5 0.57 
1601 116.2 35 0.3 
1802 22.1 47.1 2.13 
2001 46.3 28.9 0.62 
2003 65.2 77.2 1.18 
2005 - 49.6 110.7 
2101 496.2 437.4 0.88 
2103 100.4 123.9 1.23 
2302 18.5 326.8 17.62 
2401 66.9 190.5 2.85 
2701 16.5 - 0.09 
2702 29.9 8.1 0.27 
2802 43.1 30.2 0.7 
2803 201 3.1 0.02 
2805 55.7 10.8 0.19 
3001 1053.4 1344.4 1.28 
3101 48.4 52.2 1.08 
3201 48.3 81.1 1.68 
3501 10.9 21.5 1.97 
3602 68 57.1 0.84 
3606 137.4 71.4 0.52 
3703 64.7 18.7 0.29 
3801 69.7 - 0.02 
4001 50.1 148.5 2.96 
4004 - 16.6 36.94 
4202 41.7 96.1 2.3 
4204 68.5 112 1.63 
4304 - 94.5 210.86 
4501 80.2 40.1 0.5 
4601 97.7 - 0.02 
4603 67.6 9.4 0.14 
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4701 111.8 24 0.21 
4805 37 15.8 0.43 
5101 - 11.8 26.37 
5301 113.2 41.7 0.37 
5302 29.1 66.3 2.28 
5304 130.1 33.2 0.26 
5401 66.1 50.5 0.76 
5403 37 70.3 1.9 
5501 30.8 46 1.49 
5503 44 20.3 0.46 
5601 30.2 134.3 4.45 
5602 123.9 - 0.01 
5604 107.3 47.1 0.44 
5607 134.2 44 0.33 
5701 94 58.5 0.62 
5703 153 46.3 0.3 
5803 52 - 0.03 
6002 86.3 10 0.12 
6101 45.6 36.5 0.8 
6102 - 81.9 182.72 
6201 21.3 23.3 1.1 
6202 57.5 30.1 0.52 
6302 - 18.8 41.85 
6403 56.9 101 1.77 
6405 89.6 83.9 0.94 
6501 34.3 62.6 1.82 
6502 13 29.7 1.82 
6601 50.6 45.4 0.9 
6602 50.7 - 0.03 
6604 51.1 38.1 0.74 
6703 93.7 36.8 0.39 
6705 50.7 73.9 1.46 
6706 68.4 - 0.02 
6801 34.3 - 0.04 
6802 5.1 21 4.12 
6803 5.1 7.4 1.45 
7102 - 50 111.56 
7203 - 74 165.11 
7204 - 31.3 69.82 
7302 101.1 85.9 0.85 
7402 17.1 170.5 9.98 
7501 23.9 45.6 1.91 
7502 24.2 17.4 0.72 
7503 6.7 18.9 2.82 
7504 36 62.8 1.75 
7505 6.3 7.4 1.18 
7506 87.4 36.8 0.42 
7601 14 10.5 0.75 
7701 34.8 49.5 1.42 
7702 136.8 82.9 0.61 
7704 51.6 36.8 0.71 
7801 10.3 17.2 1.68 
7802 - 17.1 38.2 
8001 85.2 32.7 0.38 
8101 34.4 16.1 0.47 
8102 9.5 45.2 4.74 
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8104 88.1 39.6 0.45 
8105 29.2 33.6 1.15 
8106 140.9 97.4 0.69 
8107 - 138.2 308.15 
8108 - 130.6 291.37 
8109 - 35.1 78.26 
8202 72.1 - 0.02 
8203 16.6 14.4 0.87 
8204 177.6 191.2 1.08 
8205 106.8 46.3 0.43 
8206 - 23.8 53.1 
8301 12.2 35.9 2.95 
8302 147.5 96.4 0.65 
8403 203.7 383.7 1.88 
8404 83.8 66.2 0.79 
8405 18.2 31.6 1.74 
8501 49.4 87.9 1.78 
8502 44.4 75.6 1.7 
8803 16.6 15.5 0.93 
9101 27.1 73.2 2.71 
9102 - 46.2 103.01 
9103 - 30.3 67.51 
9104 - 7.8 17.35 
9201 15.9 36.6 2.3 
9205 62.4 71 1.14 
9501 - 8 17.84 
9602 104 70.6 0.68 
 
Legend to Table 4.4: 
MW = molecular weight; pI = pH range; SSP number = the number that the computer assign to the protein spots; - = 
protein absent. 
 
Figure 4.10 is another way of presenting the data. It shows two scatter plots which shows the 
relatedness of the small Beijing cluster duplicate protein gels (Figure 4.10A), as well the relatedness 
between the protein spots of the small Beijing cluster and the atypical Beijing strain (Figure 4.10B). 
The intensity of each spot from the one strain is plotted on a log scale against the intensity of the 
same spot from the other strain. If a spot falls above or below the centre line (black line in both 
graphs, Figure 4.10) the spot’s intensity for the two different strains are not same and if the spot falls 
on the centre line the spot’s intensity is the same for both strains. The green line in Figure 4.10A and 
4.10B is the regression line that is generated from the plot, and the red and blue parallel lines in the 
graphs will appear when a fold-factor range (e.g. 2-fold, 3-fold, or 4-fold) are chosen. All the spots 
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that lie between these two lines in the graphs (Figure 4.10A and 4.10B) have intensities that fall 
within the selected fold-factor range. The correlation coefficient is represented by r in the graphs. A 
correlation coefficient of 1.00 indicates that the spots for the two different strains are the same and a 
low correlation coefficient (e.g. 0.3) indicates that the spots are different in the two strains. The 
correlation coefficient for the small Beijing cluster duplicates is almost 1.00 (Figure 4.10A), which 
is what would be expected, and the correlation coefficient for the small Beijing cluster and the 
atypical Beijing cluster is low (Figure 4.10B), which is an indication of the un-relatedness of the two 
strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Scatter Plot of the Small Beijing cluster and Atypical Beijing strain. 
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4.5 DISCUSION AND CONCLUSION 
 
There could be many reasons why Beijing cluster 220 (large Beijing cluster) is more successful in 
transmitting to a secondary host than Beijing cluster 6018 (small Beijing cluster). One of the 
reasons could be that cluster 6018 did not have the same opportunities to transmit as cluster 220, but 
if we consider the time period when the two strains were collected (Table 1), it suggests that cluster 
6018 had the same opportunity to transmit than cluster 220. The protein expression profiles for the 
two strains are very different indicating there are differences between the two strains and some of 
the differentially expressed proteins might give insight into why the one strain is more successful 
than the other, which is from the same strain family. The protein expression comparisons between 
the large and small typical Beijing clusters show 120 protein spots of which 64 were differentially 
expressed. This is over half and far higher than would be expected. Even though the large and small 
Beijing clusters belong to the same strain family, the two clusters seem to be very different in terms 
of their ability to transmit. Both have the typical Beijing characteristics and the Beijing strain family 
is one of the most dominant M. tuberculosis strain families, so why is the small cluster not as 
successful? Therefore one would expect that the expression profiles of the two clusters be different. 
It would be very interesting to find out what proteins are different between the two clusters that 
cause the one to be more successful than the other. Other factors (host and environmental) might 
also play a role, but for this study we focused on the proteins that might play a role. One should also 
bear in mind that the 64 differentially expressed spots are mostly the same proteins in both strains 
but the protein expression is different, its only a few proteins that are present in the one strain but 
absent in the other. The computer program used to analyse the 2-D gels is also very sensitive so 
minute differences will be detected.  
 
The protein expression profiles of the typical and atypical Beijing strains are also different. Fifty-
nine (59) differentially expressed proteins were found when the protein expression profiles of the 
 
85 
 
large typical Beijing cluster and atypical Beijing cluster were compared. This is less than the large 
typical Beijing vs. the small typical Beijing cluster, yet these strains are more phenotypically and 
genetically divergent. An explanation might be that the atypical Beijing cluster is also seen as a 
“large cluster”/high transmitter, like the large typical Beijing cluster, it is also successful in its ability 
to transmit. Similar bacterial-related factors might play a role in the success of transmission of these 
clusters (large typical and atypical Beijing) that might result in a more similar protein expression 
profile than large typical Beijing cluster vs. small cluster. Overall there is a large divergence 
between total protein spots observed (ranges from 293 (high) to 120 (low)). This is a very large 
difference for such similar organisms. One would think that the protein expression profiles of the 
high and low transmitted strains would be very different. The large cluster, which transmits more, is 
therefore more virulent than the small cluster. Therefore more genes might be upregulated or more 
proteins that play a role in transmission/virulence are expressed in the large cluster. One might 
wonder whether this suggest inaccuracies in the 2D gel electrophoresis technique? The protein 
extractions from the three different Beijing clusters (large typical, small typical, and atypical) were 
done in duplicate (biological duplicates) and the 2D gels containing the protein spots from the 
different clusters were also done in duplicate. The duplicate gels were exactly the same, which is an 
indication that the laboratory error was minimal (I would not say that there was absolutely no 
laboratory error). One limitation of the computer program that is used to analyse the 2D gels is that it 
is very sensitive. Any background that might be on the 2D gels will be scored as protein spots 
therefore manual analysis of the gels together with the 2D gel program is needed. And the reason for 
the large difference between the protein expression profiles of the three clusters might be that the 
program recognises very minute changes. 
Unfortunately due to time constraints differentially expressed proteins between the three clusters 
could not be identified yet and therefore there was also no time to investigate other comparisons for 
example the protein expression profiles between two different clinical isolates from the same cluster 
as well as secreted proteins. The next step now would be to sequence the differentially expressed 
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proteins using MALDI TOF analysis, to identify the proteins which might play a role in the success 
of one strain and the failure of the other. 
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CHAPTER 5 
 
 
 
MATERIALS AND METHODS 
 
 
In this chapter the methods will be described, followed by a list of buffers and solutions at the end 
of this chapter. 
 
5.1 DRUG RESISTANCE GENOTYPING 
 
Mini-cultures for the preparation of DNA templates for PCR reactions 
The sputum samples were decontaminated by standard procedures (3) as follows. An aliquot of 
500ml of a NaOH/NaCl solution was added to 500ml of each sputum sample and mixed for 20 
minutes. The samples containing the NaOH/NaCl solution were centrifuged for 10 minutes at 
1200g. The supernatant from each sample was removed and the remaining pellet was re-suspended 
in 1.5ml 1XTE-buffer and centrifuged for 10 minutes at 12000g. The supernatant was removed and 
the resulting pellet was re-suspended in 1ml of 1XTE-buffer. In preparation for the mini-cultures, 
the decontaminated and liquefied sputum samples (1ml) were centrifuged for 20 minutes at 
14000xg, after which the supernatant was removed, and 500µl BACTEC medium, containing 100µl 
Panta Plus, were added to each sample. The mini-cultures were then incubated at 37°C. After 7 days 
of incubation, the mini-cultures were centrifuged for 20 minutes at 14000xg, and most of the 
supernatant was from each sample was discarded, leaving approximately 100µl of supernatant 
behind. The bacterial cell pellet was dissolved in the remaining 100µl supernatant and boiled for 20 
minutes at 100°C. These crude DNA templates were used for PCR reactions. 
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PCR amplification of various genes 
DNA amplifications were executed in 100µl reaction volumes. The PCR master-mix consisted of 
5µl 10Xreaction buffer, 1µl MgCl2, 4µl deoxyribonucleotide triphosphates (dNTPs) (0.2mM of 
each dNTP), 0.25µl Forward primer (10pM), 0.25µl Reverse primer (10pM), 0.15µl/sample Hotstar 
Taq polymerase, ~ 5µl of the crude DNA template, and dH2O to make up a final volume of 50µl. 
Reaction mixtures were heated in a thermal cycler (GeneAmp PCR System 2400, Applied 
Biosystems, Foster City, CA 94404, USA) as follows: an initial activation step of 15 minutes at 
95ºC, followed by 40 cycles of a denaturing step at 94ºC for 1 minute, an annealing step at Tm for 1 
minute, and an extension step at 72ºC for 1 minute. A final extension was done at 72ºC for 10 
minutes. The primers used for the PCR reactions are tabulated in Table 1. The PCR products were 
loaded onto a 1.5% agarose gel (SeaKem® LE Agarose, Cambrex BIO Science Rockland, USA) 
prepared by adding 1.5g agarose to 100ml 1XTBE buffer. The gel was then electrophoresed for 30 
minutes to 1 hour at 80V and visualized under ultra violet light using the Kodak Digital Science 
Electrophoresis Documentation and Analysis System 120 (Vilber Lourmat, France). 
 
TABLE 5.1. Primers used for PCR reactions. 
Target 
gene Primer Tm (°C) 
Product  
Size (bp) 
rpoB 
rpoB For 5' TGGTCCGCTTGCACGAGGGTCAGA 3’ 78 
437 
rpoB Rev 5' CTCAGGGGTTTCGATCGGGCACAT 3’ 76 
katG 
RTB 59 5' TGGCCGCGGCGGTCGACATT 3’ 
66 804 
RTB 36 5' TCGGGGTCGTTGACCTCCCA 3’ 
inhA  
promotor 
P5 5' CGCAGCCAGGGCCTCGCTG 3’ 
60 246 
P3 5' CTCCGGTAACCAGGACTGA 3’ 
IS6110 
IS6110 XhoI 5' TTCAACCATCGCCGCCTCTAC 3’ 
62 270 
954.19 5' AATCGTTGATGCTGGCGCTATGAACC 3’ 
Esat-6 For 5' GAGCAGCAGTGGAATTTCGC 3’ 
Esat-6 Rev 5' GAAGGCAACGTCACTGGG 3’ 
References for primers: IS6110 primers=(1), rpoB, katG, inhA primers=(6) 
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5.2 DNA SEQUENCING 
PCR-products were purified using the ExoSAP-IT Clean-up enzyme (AEC-Amersham, UK). Two 
microliters (2µl) of enzyme (ExoSAP-IT) were added to 5µl of PCR-product after which the 
mixture was incubated at 37ºC for 15 minutes. The enzyme was then inactivated, by heating the 
samples at 80ºC for 15 minutes. Direct sequencing of the purified, diluted PCR products was done 
with an ABI PRISM DNA Sequencer (Model 3100 PERKEN ELMER, AME Bioscience, Norway) 
using the forward primer. 
 
5.3 DNA FINGERPRINTING 
 
5.3.1 Spoligotyping 
Spoligotyping is the PCR amplification of a unique highly polymorphic locus (DR locus) in the 
genome of M. tuberculosis (2). The DR locus consists of directly repeated sequences, DRs, of 36 bp 
each, which are interspersed by non-repetitive variable repeat sequences, each 35 to 41 bp in length, 
which in combination is termed DVRs (2). This method detects the presence or absence of 43 
unique DVRs by line-blot hybridisation. It has been shown previously that the DR locus is highly 
polymorphic in different M. tuberculosis strains (5), which makes this a good method for genotypic 
classification and strain differentiation. 
 
Spoligotyping was done using the international standardised spoligotype method (2). PCR 
amplifications were done in 50μl reaction volumes and the PCR mix consisted of 5μl 10xreaction 
buffer (without MgCl2), 5μl MgCl2, 4μl dNTPs (0.2mM of each dNTP), 4μl forward primer (DRa-
biotinilated), 4μl reverse primer (DRb), 0.2μl Taq polymerase (5U/μl) (Promega), DNA template 
(20ng), and dH2O to male up a final volume of 50μl. The primers used are tabulated in Table. DRa: 
5’-GGT TTT GGG TCT GAC GAC-3’, biotinilated at the 5’-end, and DRb: 5’-CCG AGA GGG 
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GAC GGA AAC-3’. The reaction mixtures were heated in a thermal cycler as follows: An initial 
denaturing step of 3 minutes at 96ºC, followed by 20 cycles of a denaturing step at 96ºC for 1 
minute, an annealing step at Tm of 55ºC for 1 minute, and an extension step at 72ºC for 30 seconds. 
A final extension was done at 72ºC for 5 minutes. 
 
After completion of the amplification of the DNA samples spoligotyping was done using the 
following protocol. A spoligotype membrane (Isogen, Life Science, Lagedijk Noord, 3401 VA 
IJsselstein) containing denatured sequence specific oligonucleotide probes covalently linked to it 
was incubated at room temperature for 5 minutes in 2xSSPE/0.1%SDS. A 20μl aliquot of each PCR 
product was added to 150μl 2xSSPE/0.1%SDS and denatured for 10 minutes at 100ºC and 
immediately put on ice after denaturation was finished. After incubation, the membrane was placed 
on a support cushion in a mini-blotter (Immunetics, Cambridge, MA 02139) by aspiration. Each of 
the slots was filled with the diluted PCR products and allowed to hybridise for 1 hour at 57ºC on a 
horizontal surface without shaking. After hybridization the samples were removed from the mini-
blotter by aspiration and the membrane was removed from the mini-blotter and washed twice in 
2xSSPE/0.5%SDS at 60ºC for 10 minutes. The membrane was then incubated in 30μl 
2xSSPE/0.5%SDS containing 7.5μl strepavidin-peroxidase conjugate (Roche Diagnostics, 
Mannheim, Germany) for 45-60 minutes at 42ºC. To clear the membrane of all unbound 
strepavidin-peroxidase conjugate, the membrane was washed twice in 2xSSPE/0.5%SDS at room 
temperature after which the membrane was incubated for 60-90 seconds in 20ml of ECL detection 
fluid (AEC-Amersham, SA) and covered with a transparent plastic sheet with X-ray film. The 
developing ranged from 5-20 minutes. If necessary, the membrane can directly be used again to 
expose another film for an optimum period. After use, the membrane is stripped, by incubating it in 
1% SDS for 1 hour at 80ºC, after which it is stored in 20mM EDTA at 4ºC for further use. 
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5.3.2 IS6110 RFLP ANALYSIS 
IS6110 RFLP analysis of the M. tuberculosis strains was done according to the international 
standardised method. 
 
Extraction of M. tuberculosis Genomic DNA: 
LJ slants containing M. tuberculosis were heated at 80°C for 1 hour, to kill the bacteria. Fifty 
millilitre (50ml) polypropylene tubes were filled to approximately 2ml (conical section) with glass 
balls (20x5mm). After incubation, the samples were allowed to cool down for 5-10 minutes in a 
biosafety level 2 flow hood, where the rest of the DNA extraction procedure took place. To each LJ 
slant, 3ml of extraction buffer (pH 7.4,) were added and using a sterile 10µl plastic loop, all the 
bacteria were gently scraped loose from the LJ slants and transferred to the tubes containing the 
glass balls. To each of the scraped slants, another 3ml of extraction buffer were added to get the 
remains of the cells left in the bottles. The tubes were then vortexed vigorously for approximately 2 
minutes. To the vortexed tube containing the bacterial cell suspension, 500µl of lysozyme (Roche, 
Germany) with a concentration of 50mg/ml and also 2.5µl of RNaseA (Roche, Germany) with a 
concentration of 10mg/ml, were add. The tubes were gently inverted (not shaken) to mix and were 
then incubated at 37°C for 2 hours in a preheated oven. Volumes of 600µl of 10xProteinase K 
buffer and 150µl Proteinase K with a concentration of 10mg/ml were added to the bacterial cell 
suspension. The tubes were mixed gently by inversion and were incubated at 45°C over night. Five 
millilitres (5ml) of phenol/chloroform/isoamylalcohol (PCI) solution in a ratio of 25:24:1 were 
added to the cell suspension and mixed gently every 30 minutes for 2 hours at room temperature. 
The tubes were then centrifuged at 3000rpm for 20 minutes at room temperature. This step was 
included to ensure complete phase separation. Five millilitres (5ml) of chloroform/isoamylalcohol 
(CI) solution with a ratio of 24:1 were added into new sterile 50ml polypropylene tubes and by 
using a 5ml pipette, the top phase containing the DNA were carefully collected without taking up 
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any of the interface and were transferred to the new sterilised polypropylene tubes containing the CI 
solution. The tubes were mixed gently by inverting them and the centrifugation step was repeated. 
The tubes were then centrifuged at 3000rpm for 20 minutes at room temp. To new sterile 50ml 
polypropylene tubes, 600µl of 3M sodium-acetate (NaAc) at pH 5.2 were added and, using a 5ml 
pipette, the top phase containing the DNA was carefully collected, without taking up any of the 
interface, and transferred to the new sterilised polypropylene tubes containing the NaAc solution. 
Seven millilitres (7ml) of ice-cold isopropanol were added and the tubes were inverted gently back 
and forth until DNA became visible. The precipitated DNA was fished out immediately, using a 
thin glass rod, and the rods containing the DNA were placed into 15ml tubes containing 1ml of 70% 
EtOH for 10 minutes. The 1.5ml tubes and glass rods were then incubated at room temperature for 
±2.5 hours, to dry the DNA. Once the DNA was dry, it was re-hydrated by adding 300–600µl of TE 
buffer (pH 8.0), and release from the glass rods by mixing it slowly. The DNA was allowed to re-
dissolve by incubating it at 4°C overnight or at 65°C for 2 hours, after which it was and stored at -
20°C. 
 
PvuII Restriction Endonuclease Digestion 
The concentration of the DNA was determined spectrophotometrically. The PvuII digestion of the 
DNA was carried out by adding 10µl of 10Xrestriction buffer, 6µg of DNA, 30U of the restriction 
enzyme PvuII endonuclease to a 1.5ml tube and made up with ddH2O to a final volume of 100µl. 
The mixture was vortexed and incubated at 37°C for 3–16 hours after which the PvuII enzyme was 
inactivated by incubating the tubes at 65°C for 10 minutes. 
 
Gel Electrophoresis of Restricted DNA 
Eight microliltres (8µl) of the PvuII digested DNA was run on a 1% agarose gel test gel to 
determine whether the PvuII digestion was complete, and if the DNA was at the correct 
concentration. The DNA was separated at 1.45V/cm for 16 hours/overnight, or 4V/cm for 4 hours 
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and to visualise the digested DNA, the gel was stained in 500ml 1xTBE containing 50µl of a 
10mg/ml ethidium bromide and viewed under a 245nm UV light box to visualise the digested DNA 
bands. 
 
 A final gel was then prepared and the remaining PvuII-digested DNA (92µl) was precipitated as 
follows and run on the gel: Nine microlitres (9µl) of 3M Sodium Acetate (pH5.2) and 300µl ice 
cold 100% EtOH were added to the digested DNA and the tubes were mixed gently. The tubes were 
then incubated at -20°C for 16 hours/overnight. The PvuII-digested DNA was centrifuged at 
10 000xg for 30 minutes at 4°C to pellet the DNA. A suction device attached to a sterile 10ml 
plastic pipette was used to slowly and carefully aspirate the supernatant down to ~50µl. The DNA 
pellet was washed again with 500µl 70% ice-cold ethanol after which it was centrifuge at 10 000xg 
for 30 minutes at 4°C to pellet the DNA once again. The supernatant was again aspirated down to 
~50µl and the DNA pellet was allowed to dry at room temperature for 16 hours/overnight to 
remove all residual 70% ethanol. The DNA was re-dissolved in 1x loading buffer/Internal 
Molecular Weight Marker (Marker X) and mixed gently every hour at 4°C for 16hours/overnight or 
65°C for 4hours. A 0.8% agarose gel were prepared and the PvuII-digested DNA samples were 
loaded onto the gel and was separated and visualised as previously described. 
 
Southern Transfer of the Fingerprinting Gel 
The gel was placed inverted into a flat plastic container and the DNA in the gel was denatured by 
incubating in 500ml denaturing buffer at 25°C for 30 minutes with gentle shaking. The denaturing 
solution was aspirated off and the gel was neutralized with 500ml neutralizing buffer and incubated 
at 25°C for 30 minutes with gentle shaking. A nylon membrane (Hybond N+) was labelled to allow 
further recognition by spotting 0.2µl aliquots of orientation marker onto the membrane. The 
membrane was hydrated in ddH2O for a few seconds and was immediately transferred to a 
20XSSPE solution to allow equilibration. The Southern Blot apparatus was set up by soaking a 
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large sheet of Whatman 3MM paper (46x57cm) in 20XSSPE and placing it on a blotting tray. The 
gel was then placed in its inverted orientation, onto the Whatman 3MM paper. By using a surgical 
blade, the edges of the gel as well as the wells were cut away and all air bubbles were removed 
from under the gel. Strips of parafilm were placed around the gel ensuring that they are positioned 
right up against the gel and the Hybond N+ membrane were placed onto the agarose gel with the 
orientation markers and labelled facing the gel. Air bubbles were removed from between the gel and 
membrane. One large sheet of Whatman paper (46x57cm) was cut into two identical pieces such 
that they overlap the gel by 5 to 10mm on each side. Both pieces of paper were wet in 20X SSPE 
(pH1.4) and place one on top of the other on the nylon membrane. Again air bubbles were removed.  
 
In order to create a capillary flow of buffer through the gel and membrane, folded paper towels 
were stacked onto the Whatman 3MM papers. The blotting tray was filled with 20XSSPE (pH7.4) 
and the Southern transfer was allowed to proceed for 16 hours (or overnight). When the transfer 
was finished, the nylon membrane was removed and washed in 2XSSPE for 10 minutes. The 
membrane was placed between 2 sheets of Whatman 3MM paper and baked at 80ºC for 2 hours. 
The membrane was then sealed in a plastic sleeve and was stored at 4ºC until further use. 
 
Preparing the IS6110 Probe by PCR Amplification 
The PCR amplification mixture was prepared by adding, in order, 9.375µl Sterile nuclease free 
dH2O to 5µl Q-Solution, 2.5µl 10× PCR Buffer, 2µl MgCl2 (25mM), 4µl dNTPs (10mM), 1µl of 
each IS6110 primer (50pmol/µl) and 0.125µl HotStarTaq DNA polymerase to a total volume of 
25µl. 
 
The amplification process was started by incubating the samples at 95ºC for 15 minutes. Then the 
samples were incubated at 94ºC for 1 minute, for 35-45 cycles, followed by incubation at 62ºC for 1 
minute, 72ºC for 1 minute, and lastly incubation at 72ºC for 10 minutes. After the PCR 
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amplification was complete, 5µl aliquots of the PCR products were run on a 2% agarose gel 
(containing 1×TBE pH8.3) followed by staining with ethidium bromide. The IS6110 PCR products 
were purified with a clean up kit (Wizard SV Gel & PCR Clean-up System) according to the 
manufacturer’s specifications. The DNA was eluted in nuclease free H2O and the concentration of 
the probe was determined spectrophotometrically by reading the optical density at 260nm.  
[OD260nm = 50µg/µl of double stranded DNA] 
 
Labelling the IS6110 & Internal Marker Probes 
A total of 200ng of probe DNA were added to a 0.5ml tube and made up to a volume of 15µl with 
nuclease free H2O. The tube was then incubated at 100ºC for 5 minutes to denature the probe DNA 
and immediately after was put on ice for 5 minutes to ensure that the denatured DNA stays in single 
stranded form so that hybridization can take place. The probe was labelled by adding 15µl of Horse 
Radish Peroxidase (HRP) to it. A total of 15µl of Gluteraldehyde solution were added to the tube 
containing the probe and HRP and mixed well. The tube was then incubated for 10 minutes at 37ºC 
and then added to the membrane. 
 
Prehybridisation and Hybridisation 
The nylon membrane was re-hydrated by incubating it in 500ml dH2O. The membrane was then put 
in a plastic sleeve (25x35cm) containing 48ml of ECLTM Gold Hybridization Buffer. All air bubbles 
were removed from the bag. The plastic sleeve containing the membrane and buffer was then sealed 
and the ECLTM Gold Hybridization Buffer was spread over the membrane by gently rolling a 10ml 
pipette over the bag. The plastic sleeve containing the membrane and ECL buffer was then put into 
a flat plastic container. A second plastic sleeve containing 500ml of H2O were placed on top of the 
plastic sleeve containing the membrane and pre-hybridised by incubating the plastic container in a 
shaking water bath at 42°C for at least 60 minutes at 90rpm. Hybridization was started by removing 
the sleeve containing the membrane from the water bath, one corner of the sleeve was cut off and 
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the labelled probe was added directly to the ECLTM Gold Hybridization Buffer. Air bubbles were 
removed and the membrane was placed back in the water bath and hybridised at 42°C for 16 hours 
with shaking at 90rpm. After hybridisation was complete, the membrane was removed from the 
sleeve and washed twice by adding 400ml pre-warmed (to 42°C) Primary wash (Section … Buffers 
and Solutions), in a water bath at 42°C for 20 minutes shaking at 90rpm. The membrane was then 
washed twice with 400ml 2XSSC for 5 minutes at room temperature on a shaker.  
 
Detection of Hybridisation 
To confirm whether hybridisation took place, 4ml of each of the two Amersham ECLTM Detection 
Reagents were mixed together and added to the membrane. The detection fluid was spread over the 
membrane for 90 seconds. All excess Amersham ECLTM Detection fluid was removed and the 
membrane was exposed to x-ray for 1 minute to up to 2 hours. 
 
Stripping the membrane 
To strip the membrane from all probe and DNA, the membrane was placed in a plastic container 
containing 400ml of boiling 0.1% SDS. The container was then placed on a shaker at room 
temperature for 60 minutes and the membrane was put in a clean plastic sleeve stored at 4ºC.  
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5.3.3 DETERMINATION OF THE PRESENCE OR ABSENCE OF REGIONS OF 
DIFFERENCE 
Each Beijing strain from each patient was subjected to PCR amplification in a reaction mixture 
containing 0.2g DNA template, 5ul Q buffer, 2.5ul 10xbuffer, 2ul 25mM MgCl2, 4ul 10mM 
dNTPs, 1ul of each primer (50pmol/ul) (4) (Table 4) and 0.125ul HotStarTaq DNA polymerase 
(QIAGEN, Germany) and made up to 25ul with dH2O. Amplification was initiated by incubation at 
95°C for 15 minute, followed by 35 to 45 cycles at 94°C for 1 minute, annealing temperature (62˚C) 
for 1 minute, and 72°C for 1 minute. After the last cycle, the samples were incubated at 72°C for 10 
minutes. PCR amplification products were electrophoretically fractionated in 3.0% agarose in 
1xTris-buffered EDTA, pH8.3, at 6 V/cm for 4 hours and visualized by staining with 
ethidiumbromide. The existence of a mutational event was determined by the presence or absence 
and the size of the respective PCR product. 
 
Table 5.2. Primers used to determine regions of difference. 
OLIGO NAME SEQUENCE 
RD105F 5’ACA GCG CGG GTC ATA TCA C 3’ 
RD105INT 5’GCA ACA CCC GCT TGT CTT TG 3’ 
RD105R 5’AAC CAG CTC CTC GAC GCT ATC 3’ 
RD181F 5’AAA TCC GCC CAT ACC CGT C 3’ 
RD181R 5’AGC TTC GAC TGG CCA TAG GC 3’ 
RD150F 5’AGT GCT GGC AAT AGC GGT TG 3’ 
RD150INT 5’CAC CGG CAC TTA CCA TCT CG 3’ 
RD150R 5’CCA GCA CTT GTT GCA ACT TCG 3’ 
RD142F 5’CCG GTG GTA CGG GTA TTT CC 3’ 
RD142INT 5’GCT CGA GCA TGA TCA GCA AAG 3’ 
RD142R 5’TAG CAC CAG TAC CGG ATG TCC 3’ 
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5.4 CULTIVATION OF M. TUBERCULOSIS STRAINS 
 
Strains were first cultured on solid media slants. The solid medium used in this study to culture M. 
tuberculosis was Lowenstein-Jensen (LJ) medium which is an egg-based medium. The medium 
contains inhibitors to keep contaminants from outgrowing M. tuberculosis. After 2-3 weeks, small 
buff coloured colonies that had a breadcrumb (Figure 5.1) appearance became visible. 
 
 
Figure 5.1. M. tuberculosis colonies on an LJ slant. 
 
From the positive LJ, a few colonies were picked and inoculated into liquid medium known as 
Middlebrook 7H9 medium (Becton, Dickinson and Company, Sparks, USA), which is an agar-
based medium (ref) (supplemented with 10% albumin-dextrose-catalase (ADC), 0.2% (v/v) glycerol 
(Merck Laboratories, Saarchem, Gauteng, SA) and 0.1% Tween80 (Merck Laboratories)). The 
bacteria were cultured in filtered-cap tissue culture flasks (Greiner Bio-one, Maybach Street, 
Germany) without shaking at 37 °C. An initial culture of 5ml was prepared and incubated for ~ 2 
weeks until the culture had a milky appearance and reached an optical density (OD600) of mid-
logarithmic phase (0.6-0.8). This starting culture was used to make 1:100 dilution sub-cultures until 
the required volume of bacteria was reached (Figure 5.2). 
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Figure 5.2. Diagrammatic illustration of how M. tuberculosis was cultured for protein extraction. 
 
The cultures were tested continuously for contaminants by doing a Ziehl-Neelsen (Zn) test (to make 
sure that the organism present is M. tuberculosis) as well as plating a drop of the culture onto a 
blood agar plate (M. tuberculosis does not grow on blood agar). M. tuberculosis is classified as 
acid-fast bacteria due to their impermeability by certain dyes and stains. Despite this, once stained, 
acid-fast bacteria will retain dyes when heated and treated with acidified organic compounds. The 
acid-fast staining method for M. tuberculosis that we used was the Zn stain. When this method is 
used, the M. tuberculosis smear was fixed (heated for 2 hours at 100°C), stained with carbol-fuchsin 
(a pink dye) (Becton, Dickinson and Company, Maryland, USA), and decolorized with acid alcohol. 
The smear was then counterstained with methylene blue (Becton, Dickinson and Company, 
Maryland, USA). Acid-fast bacilli appear pink in a contrasting background (Figure 5.3). 
5ml culture, 
Incubate ~2 wks 
10ml culture, 
Incubate ~ 2 wks 
(OD=0.8) 
Final culture, 40ml, 
Incubate ~ 2 wks (OD=0.8) 
Zn + blood agar 
To get rid of LJ 
medium and 
clumps 
Zn + blood agar To get rid of 
further 
clumping 
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Figure 5.3. The white arrow indicates acid-fast M. tuberculosis stained with ZN stain. 
 
5.5 PROTEIN EXTRACTIONS OF M. TUBERCULOSIS WHOLE CELL LYSATE 
After the M. tuberculosis culture reached an OD600 of mid log phase (0.6-0.8), it was centrifuged 
(Eppendorf, Centrifuge 5810R) at 3000rpm for 20 minutes at 20ºC. The supernatant was discarded 
and the pellet re-suspended in 1ml Phosphate buffer saline (PBS), pH 7.4, containing 1% (v/v) 
Tween. The suspension was then transferred to a 2ml screw cap tube and centrifuged at 6000rpm 
for a further 5 minutes. The supernatant was discarded and the resulting pellet was washed in 1ml 
PBS and centrifuged at 6000rpm for 5 minutes. The supernatant was discarded and an equal volume 
(approximately the same size as the pellet) of silica hybaid beads (Bio 101, Vista, USA) and 
approximately 200-500μl of Lysis buffer (Sigma-Aldrich, Missouri, USA) (depending on the size of 
the pellet) were added to the cell pellet. The tube containing the bacterial pellet, beads and Lysis 
buffer was then vortexed to mix the beads and Lysis buffer with the cell pellet. The mixture was 
then incubated at 80ºC for 20 minutes after which it was cooled to room temperature. The bacterial 
cells were ribolysed using a FastPrep FP120 ribolyzer (Bio101 SAVANT, Vista, USA), with 
highest intensity (6.5 m/s) for 2-4×45 seconds with 1 minute of cooling on ice between the cycles, 
The cells were then incubated at 100ºC for 5 minutes allowed cool to room temperature, and 
centrifuged for 10 minutes at 13 000 rpm. The supernatant, which contained the whole cell lysate 
proteins were then transferred to a clean 2ml eppendorf tube and stored at -20ºC until needed for 
further analysis. 
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5.6 DETERMINATION OF PROTEIN CONCENTRATIONS 
The Bradford protein assay in which a differential colour change of a dye occurs in response to 
various concentrations of protein, were used to determine the concentrations of the extracted whole 
cell lysate proteins. The linear concentration range is 0.1-1.4 mg/ml of protein, using BSA (bovine 
serum albumin) as the standard protein. To determine the concentrations of the proteins in this study 
a total of 8 dilutions ranging from 0.2 to 0.9mg/ml, were prepared (Table 5.3) and used to establish 
a standard curve from which the unknown protein concentrations could be determined. 
 
Table 5.3. Range of BSA used for standard curve 
BSA dilutions 
BSA 
range BSA stock (µl) H2O (µl) 
Blank 0 20 
0.1 0.7 19.3 
0.2 1.5 18.5 
0.4 2.9 17.1 
0.5 3.6 16.4 
0.6 4.4 15.6 
0.8 5.8 14.2 
1 7.24 12.75 
 
One microlitre (1µl) of each sample was added to 19µl of dH2O. The Bradford reagent (containing 
BSA) was diluted (1 part reagent to 3 parts milliQH2O) with milliQH2O to a volume according to 
the number of protein samples. A volume of 980µl diluted Bradford reagent was then added to each 
standard and sample, and vortexed to mix the reagent with the BSA standards and samples. The 
mixtures were then incubated at room temperature for 5 minutes and the ODs of the samples were 
taken in duplicate at wavelength 595 with a spectrophotometer. 
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Protein purification 
The proteins were purified using the ReadyPrep 2-D CleanUp Kit (Bio-Rad Laboratories, Hercules, 
CA 94547) according to the manufacturer’s instructions. The concentrations of the proteins were 
then determined with the RC DC Protein assay (Bio-Rad Laboratories, Hercules, CA 94547) 
according to the instructions of the manufacturers. 
 
 
5.7 PROTEIN SEPARATION 
 
5.7.1 Isoelectric focusing 
Proteins differ from each other in terms of their mass and charge. The first dimension (1-D) 
polyacrylamide gels used in IEF were pH4-7 IPG (immobilised pH gradients) strips (Bio-Rad, 
Laboratories, Hercules, CA 94547), which provide a supporting matrix through which proteins can 
migrate. This gel has a pH gradient from top to bottom, the top more acidic than the bottom. The 
proteins migrate through the gel until they reach their isoelectric point (the point at which their 
charge is the same as the surrounding pH).  
 
The protein samples were added to re-hydration (RH) buffer, which is used to solubilise and run 
protein mixtures during IEF. The IPG strips were then added to the protein/RH buffer mix and 
allowed to re-hydrate at room temperature for 20 hours. When re-hydration was finished the IPG 
strips containing the proteins, were electrophoresed under the following running conditions: 100V 
for 2 hours, 300V for 3 hours, 1000V for 1 hour, and 3500V for 20 hours, at 17ºC. 
 
 
 
 
105 
 
5.7.2 2-Dimensional gel electrophoresis 
For the second step of the experiment, the IPG strips were placed in equilibration buffer containing 
DTT (used for disruption of protein disulfide bonds) (Sigma-Aldrich, Missouri, USA) for 15 
minutes and then in buffer containing Iodoacetamide (an alkylating agent which aids in unfolding 
the proteins) (Sigma-Adrich, Missouri, USA) for 15 minutes. The 1-D gels were then placed on top 
of the 2-D gels, which are SDS-PAGE gels, and sealed to the 2-D gels with agarose (ReadyPrepTM 
Overlay agarose, Bio-Rad Laboratories, Hercules, CA 94547). The proteins were separated by a 
second property in a direction 90 degrees from the first. Proteins with a higher mass, migrates 
slower through the gel than proteins with a smaller mass. The proteins were therefore spread out on 
the surface of the gel. The 2-D gels were electrophoresed for 2-3 hours. 
 
5.8 PROTEIN DETECTION 
The proteins can be detected by a variety of methods but the most commonly used are silver nitrate 
and coomassie brilliant blue staining methods. For this study we made use of the silver stain 
method. 
 
The proteins were fixed in the 2-D protein gels with Fixing buffer for 1 hour. The protein gels were 
then soaked in Soaking buffer overnight. After the gels were soaked, they were washed with 
milliQH2O 3 times for 10 minutes each and then sensitised twice for 15 minutes with Sensitise 
buffer. The gels were washed 3 times for 10 minutes each with chilled milliQH2O and incubated in 
chilled (4°C) silver nitrate solution for 1.5 hours at 4°C with shaking. The silver nitrate solution was 
discarded and the gels were rinsed twice for 1 minute with milliQH2O. Developing buffer was then 
added to the gels to allow the silver nitrate to develop. As soon as the Developing buffer turned a 
yellow colour, it was discarded and replaced with fresh buffer. The new Developing buffer was 
discarded as soon as the protein spots were visible and the gels were washed with Stop buffer to 
stop the developing. The silver-stained gels were stored in Store buffer at room temperature. 
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5.9 2-D GEL ANALYSIS 
Silver stained gels were scanned and recorded using a GS-800 Calibrated Densitometer (Bio-Rad 
Laboratories, Hercules, CA 94547) and quantitative spot detection and matching was done visually 
as well as using PDQuest and Quantityone 2-D software (Bio-Rad Laboratories, Hercules, CA 
94547). Differentially expressed protein spots were excised and stored for future Mass 
spectrometric analysis. 
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5.11     LIST OF BUFFERS AND SOLUTIONS 
 
 
 
PCR BUFFERS 
 
10XTE Buffer:    10mM TRIS 
1mM EDTA 
dH2O 
 
10XTBE Buffer (pH 8.3):   0.45M Tris 
      0.44M Boric acid 
      10mM EDTA 
      dH2O to make up 1L 
 
 
SPOLIGOTYPING SOLUTIONS 
 
10XSSPE:     100mM HNa2PO4 
      1.8M NaCl 
      10mM EDTA 
      dH2O to make up 1L  
 
10% SDS:     50g SDS 
      500ml dH2O 
 
0.5M EDTA:     93g EDTA 
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      500ml H2O 
 
 
IS6110 RFLP BUFFERS AND SOLUTIONS 
 
Chloroform/isoamyl alcohol:  24:1 v/v 
 
Denaturing Buffer (5 litres):   1.5M NaCl, 
0.5M NaOH 
:      438.3g NaCl 
      100g NaOH 
 
70% Ethanol:     store at  -20ºC 
      use 'ice-cold' 
 
100% Ethanol:     store at  -20ºC 
 
Ethidium Bromide:    Final concentration 10mg/ml 
      NB: store in dark container 
 
Extraction Buffer pH 7.4 (1litre ):  5% Mono Sodium Glutamatic Acid   
50mM Tris-HCl (pH 7.4),  
25mM EDTA 
      Adjust pH with Hydrochloric Acid  
 
100% Isopropanol:     store at  -20ºC 
      use ‘ice-cold’ 
110 
 
 
Loading Buffer (pH 8.0) (100ml):  30ml 100% Glycerol 
      6mg Bromophenol blue 
      0.6g SDS 
      make up to 100ml with TE 
      store at room temperature 
 
Loading buffer/internal molecular weight marker (1X): 
      6ml TE (pH 8.0) 
      2ml loading buffer 
      6.6μl marker X (1650ng) 
      store at -20ºC 
(alternatively use PvuII digested supercoiled ladder (Gibco BRL, USA) 
 
Lysozyme (Roche, Germany):  50mg/ml in dH2O 
 
Marker X (Roche, Germany) (250ng/μl): 
(alternatively use PvuII digested supercoiled ladder (Gibco BRL, USA) 
 
Neutralizing Buffer (5 litres):  1.5M NaCl,  
0.5 M Tris-HCl (pH7.5): 
438.3g NaCl 
       302.5g Tris 
 
Orientation Marker “spotter”:  2μl Marker (0.25μg/μl) 
20μl M. tuberculosis DNA (H37Rv) (2.5μg) 
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      23μl TE 
      45μl 0.8M NaOH 
 
Phenol/Chloroform/isoamyl alcohol:  25:24:1v/v 
 
Primary wash buffer:   720g urea  
8g SDS 
25ml 20 x SSC 
dH2O to make up to 2 litres 
store at room temperature 
 
Proteinase K (Roche, Germany):  10mg/ml in dH2O 
store in aliquots at -20ºC 
 
Proteinase K buffer (pH 7.8, 500ml): 5% sodium dodecyl sulphate 
100mM Tris-HCl (pH7.8)  
50mM EDTA 
Adjust pH with HCl 
 
PvuII restriction endonuclease (10u/μl) (New England Biolabs, USA) 
 
Restriction Buffer, NE Buffer 2 (10X) (New England Biolabs, USA) 
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RNaseA (Roche, Germany):   10mg/ml in 10mM Tris-HCl (pH7.5)  
15mM NaCl 
Heat to 100ºC for 15 minute 
Allow to cool to room temperature 
Store in aliquots at -20ºC 
 
3M Sodium Acetate pH 5.5 (500ml): 204.1g Na-Ac-3H2O 
adjust pH with Glacial Acetic Acid 
store at room temperature 
 
Sodium Dodecyl Sulphate (SDS):   10% w/v 
 
SSPE Solution (20X) (pH 7.4) (5 litres): 3M NaCl 
       0.2 NaH2PO4 .H2O 
       20mM EDTA 
876.5g NaCl 
138g NaH2PO4 .H2O 
37g EDTA 
40g NaOH pellets 
adjust pH with ~8g NaOH 
store at room temperature 
 
5XTBE  (pH 8.3):     0.45M Tris 
0.44M Boric acid 
10mM EDTA 
dH2O to make up 2L 
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store at room temperature 
NB: DO NOT pH THIS SOLUTION 
 
TE (pH 8.0):     10mM Tris-HCl (pH 8.0) 
1mM EDTA 
1.211g Tris 
0.372g EDTA 
adjust by using HCl, autoclave 
store at room temperature 
 
 
CULTIVATION OF M. TUBERCULOSIS STRAINS 
 
Middlebrook 7H9 medium:   4.7g 7H9 medium 
      900ml dH2O 
      2ml Glycerol 
      0.5ml Polysorbate (Tween80) 
       
ADC:      25g BSA 
      10g Glucose 
      0.75ml Catalase 
      dH2O to make up 500ml 
 
 
EXTRACTION OF WCL PROTEINS 
 
Lysis buffer:     0.3% (w/v) SDS 
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200mM DTT (for intracellular proteins) 
      50mM Tris-HCL (pH 7.0) 
1mM PMSF (inhibit serine proteases) 
      1 Protease inhibitor tablet 
      dH2O to make up 25ml 
 
PBS (pH 7.3):     8g NaCl 
      0.2g KCL 
      1.15g diNaHPO4 
      0.2g KH2PO4 
      1% Tween80 
      dH2O to make 1L 
 
 
 
2-D GEL ELECTROPHORESIS SOLUTIONS 
 
re-hydration (RH) buffer:   8M Urea 
      2% Chaps 
      10mM DTT 
      2% IPg buffer 
      Bromophenol blue (trace amount) 
Equilibration buffer 1 (containing DTT): 0.375M Tris-HCL (pH 8.8) 
      6M Urea 
      30% Glycerol 
      2% SDS 
      2% DTT 
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Equilibration buffer 2 (containing Iodoacetamide): 
      0.375M Tris-HCL (pH 8.8) 
      6M Urea 
      30% Glycerol 
      2% SDS 
      1g Iodoacetamide 
 
Electrophoresis buffers: 
Cathode buffer:    192M Glycine (pH 8.3) 
      pH with Tris 
      add 0.1% SDS 
      milliQH2O to make up 1L 
 
Anode buffer (2x):    0.375M Tris (pH 8.8) 
      pH with AcOH 
      milliQH2O to make up 1.5L 
  
Fixing buffer:    50% MeOH (Merck, Darmstadt,  
                                                                       Germany) 
      5% AcOH (Merck, Darmstadt,  
                                                                       Germany) 
 
Soak buffer:     50% MeOH 
 
Sensitise buffer:    0.02% Na2S2O3 (Sigma-Aldrich,  
                                                                        Missouri, USA) 
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Silver nitrate solution (Sigma-Aldrich): 0.1%  
 
Developing buffer:    0.04% formalin (Sigma-Aldrich) 
      2% Na2CO3 (Sigma-Aldrich) 
 
Store buffer:     1% AcOH 
 
 
 
 
